Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Preliminary additions and deletions (Russell 3000® Index)
Russell Reconstitution
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Annual rebalancing of Russell Indexes
In order to maintain true representation of global equity markets and avoid capitalization and style slippage, Russell annually rebalances the entire Russell family of indexes.
Annual reconstitution ensures that the Indexes reflect the changes in the market over time and accurately represent the true opportunity set of institutional managers. Russell's U.S. and global index families reconstitute simultaneously.
2010 Reconstitution
The 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010.
View preliminary additions and deletions to the Russell Indexes
http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx
Updated June 11, 2010
Frequently asked questions
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Reconstitution schedule
June 11
Preliminary additions and deletions to the Russell Global Index, Russell 3000® and Russell Microcap® published after 3:00 p.m. PST
June 18
Updates to the list of additions and deletions
June 25
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
June 28
Final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap Indexes
#############################################################################################
Preliminary additions and deletions (Russell 3000® Index)
As of June 11, 2010
466 changes
Change Company Symbol Country Sector
Add 1ST UNITED BANCORP INC FUBC United States Financial Services
Add A H BELO CORP AHC United States Consumer Discretionary
Add ABRAXAS PETE CORP AXAS United States Energy
Add ACCENTURE PLC IRELAND ACN United States Producer Durables
Add ACCRETIVE HEALTH INC AH United States Health Care
Add ACE LTD ACE United States Financial Services
Delete ACTIVIDENTITY CORP ACTI United States Technology
Delete ADOLOR CORP ADLR United States Health Care
Delete AGFEED INDUSTRIES INC FEED United States Consumer Staples
Add ALCON INC ACL United States Health Care
Add ALEXZA PHARMACEUTICALS ALXA United States Health Care
Add ALIMERA SCIENCES INC ALIM United States Health Care
Add ALPHA & OMEGA SEMICON AOSL United States Technology
Delete AMERICAN CARESOURCE HLDG ANCI United States Health Care
Delete AMERICAN DAIRY INC ADY United States Consumer Staples
Add AMERICAN DG ENERGY INC ADGE United States Utilities
Add AMERICAN OIL & GAS INC AEZ United States Energy
Delete AMERICAN ORIENTAL BIOENG AOB United States Health Care
Delete AMERICAN REALTY INVESTOR ARL United States Financial Services
Delete AMICUS THERAPEUTICS INC FOLD United States Health Care
Delete AMPAL AMERICAN ISRAEL AMPL United States Financial Services
Delete AMREP CORP AXR United States Consumer Discretionary
Add ANTARES PHARMA INC AIS United States Health Care
Add ANTHERA PHARMACEUTICALS ANTH United States Health Care
Add AOXING PHARMACEUTICAL CO AXN United States Health Care
Add APPLIED ENERGETICS INC AERG United States Producer Durables
Add ARCTIC CAT INC ACAT United States Consumer Discretionary
Add ARLINGTON ASSET INVT AI United States Financial Services
Add ARTHROCARE CORP ARTC United States Health Care
Delete ARYX THERAPEUTICS INC ARYX United States Health Care
Delete ASCENT SOLAR TECH INC ASTI United States Energy
Delete ASIAINFO HOLDINGS INC ASIA United States Technology
Add ASPEN TECHNOLOGY INC AZPN United States Technology
Add ASPENBIO PHARMA INC APPY United States Health Care
Add ASTA FDG INC ASFI United States Financial Services
Delete AUBURN NATL BANCORP AUBN United States Financial Services
Add AVAGO TECHNOLOGIES LTD AVGO United States Technology
Add AVEO PHARMACEUTICALS INC AVEO United States Health Care
Add AXCELIS TECHNOLOGIES INC ACLS United States Technology
Add AXT INC AXTI United States Technology
Add BALLANTYNE STRONG INC BTN United States Producer Durables
Add BALTIC TRADING LIMITED BALT United States Producer Durables
Delete BANK KY FINL CORP BKYF United States Financial Services
Delete BANNER CORP BANR United States Financial Services
Delete BAR HBR BANKSHARES BHB United States Financial Services
Add BARRY R G CORP OHIO DFZ United States Consumer Discretionary
Add BEASLEY BROADCAST GROUP BBGI United States Consumer Discretionary
Add BELL MICROPRODUCTS INC BELM United States Technology
Delete BENIHANA INC BNHNA United States Consumer Discretionary
Add BERKSHIRE HATHAWAY INC BRK.B United States Financial Services
Delete BIODELIVERY SCIENCES BDSI United States Health Care
Add BIOSANTE PHARMACEUTICALS BPAX United States Health Care
Add BIOTIME INC BTIM United States Health Care
Add BOFI HLDG INC BOFI United States Financial Services
Delete BOLT TECHNOLOGY CORP BOLT United States Energy
Add BON-TON STORES INC BONT United States Consumer Discretionary
Delete BOVIE MEDICAL CORP BVX United States Health Care
Add BRIDGFORD FOODS CORP BRID United States Consumer Staples
Delete BRONCO DRILLING CO INC BRNC United States Energy
Delete BROOKLYN FEDERAL BANCORP BFSB United States Financial Services
Add CALIPER LIFE SCIENCES CALP United States Health Care
Add CALIX INC CALX United States Technology
Delete CALLIDUS SOFTWARE INC CALD United States Technology
Add CALLON PETROLEUM CO CPE United States Energy
Add CAMAC ENERGY INC CAK United States Energy
Add CAMBIUM LEARNING GRP INC ABCD United States Consumer Discretionary
Delete CAPE BANCORP INC CBNJ United States Financial Services
Add CAPITAL GOLD CORP CGC United States Materials & Processing
Add CAPSTONE TURBINE CORP CPST United States Energy
Delete CARDIAC SCIENCE CORP CSCX United States Health Care
Delete CARDIOVASCULAR SYS INC CSII United States Health Care
Delete CARDIUM THERAPEUTICS INC CXM United States Health Care
Add CASELLA WASTE SYSTEMS CWST United States Consumer Discretionary
Add CASUAL MALE RETAIL GROUP CMRG United States Consumer Discretionary
Add CDC CORP CHINA United States Technology
Delete CELL THERAPEUTICS INC CTIC United States Health Care
Delete CENTER BANCORP INC CNBC United States Financial Services
Add CENTER FINANCIAL CORP CLFC United States Financial Services
Delete CENTRAL PACIFIC FINL CPF United States Financial Services
Add CERUS CORP CERS United States Health Care
Delete CHASE CORP CCF United States Materials & Processing
Add CHATHAM LODGING TR CLDT United States Financial Services
Delete CHEVIOT FINANCIAL CORP CHEV United States Financial Services
Add CHICAGO BRIDGE & IRON CBI United States Producer Durables
Delete CHICOPEE BANCORP INC CBNK United States Financial Services
Delete CHINA AUTOMOTIVE SYSTEMS CAAS United States Consumer Discretionary
Delete CHINA BAK BATTERY INC CBAK United States Producer Durables
Delete CHINA FIRE & SEC GROUP CFSG United States Producer Durables
Delete CHINA GREEN AGRICULTURE CGA United States Consumer Staples
Delete CHINA HOUSING & LAND DEV CHLN United States Financial Services
Delete CHINA INFORMATION SEC CPBY United States Technology
Delete CHINA PRECISION STEEL CPSL United States Materials & Processing
Delete CHINA SEC & SURVE TECH CSR United States Producer Durables
Delete CHINA SKY ONE MED INC CSKI United States Health Care
Delete CHINA TRANSINFO TECHNLGY CTFO United States Technology
Delete CHINA-BIOTICS INC CHBT United States Consumer Staples
Delete CHINACAST EDU CORP CAST United States Consumer Discretionary
Add CIT GROUP INC CIT United States Financial Services
Delete CITIZENS HLDG CO MISS CIZN United States Financial Services
Add CNH GLOBAL N V CNH United States Producer Durables
Add CODEXIS INC CDXS United States Health Care
Delete COGO GROUP INC COGO United States Technology
Add COLEMAN CABLE INC CCIX United States Producer Durables
Add COMBINATORX INC CRXX United States Health Care
Add COMMERCIAL VEH GROUP INC CVGI United States Producer Durables
Delete COMMUNICATIONS SYSTEMS JCS United States Technology
Add COMPX INTERNATIONAL CIX United States Materials & Processing
Add CONEXANT SYSTEMS INC CNXT United States Technology
Add CONVIO INC CNVO United States Technology
Add COOPER INDUSTRIES PLC CBE United States Producer Durables
Add CORCEPT THERAPEUTICS INC CORT United States Health Care
Add CORE LABORATORIES N V CLB United States Energy
Add COVIDIEN PLC COV United States Health Care
Delete CREDO PETROLEUM CORP CRED United States Energy
Delete CTC MEDIA INC CTCM United States Consumer Discretionary
Delete CUBIC ENERGY INC QBC United States Energy
Add CULP INC CFI United States Materials & Processing
Add CUMULUS MEDIA INC CMLS United States Consumer Discretionary
Add CYTRX CORP CYTR United States Health Care
Add DELTA APPAREL INC DLA United States Consumer Discretionary
Add DEX ONE CORP DEXO United States Consumer Discretionary
Add DIGIMARC CORPORATION DMRC United States Technology
Add DISCOVERY COMMUNICATIONS DISCA United States Consumer Discretionary
Delete DISCOVERY COMMUNICATIONS DISCK United States Consumer Discretionary
Delete DISCOVERY LABORATORIES DSCO United States Health Care
Add DOUGLAS DYNAMICS INC PLOW United States Producer Durables
Delete DOVER DOWNS GAMING & ENT DDE United States Consumer Discretionary
Delete DUOYUAN PRINTING INC DYP United States Producer Durables
Delete DYNAMICS RESEARCH CORP DRCO United States Technology
Add DYNAVAX TECHNOLOGIES DVAX United States Health Care
Add DYNAVOX INC DVOX United States Technology
Delete EASTERN CO EML United States Materials & Processing
Delete EASTERN INSURANCE HLDGS EIHI United States Financial Services
Delete ELOYALTY CORP ELOY United States Technology
Delete EMCORE CORP EMKR United States Technology
Add EMPIRE RESORTS INC NYNY United States Consumer Discretionary
Add ENCORE BANCSHARES INC EBTX United States Financial Services
Add ENERGY PARTNERS LTD EPL United States Energy
Add ENERGY XXI (BERMUDA) LTD EXXI United States Energy
Delete ENGLOBAL CORP ENG United States Producer Durables
Add ENTERCOM COMMUNICATIONS ETM United States Consumer Discretionary
Delete ENTEROMEDICS INC ETRM United States Health Care
Delete ENTERPRISE BANCORP INC EBTC United States Financial Services
Add ENTRAVISION COMM EVC United States Consumer Discretionary
Add EURAND N V EURX United States Health Care
Delete EVERGREEN ENERGY INC EEE United States Energy
Add EVOLUTION PETROLEUM CORP EPM United States Energy
Add EXACT SCIENCES CORP EXAS United States Health Care
Add EXCEL MARITIME CARRIERS EXM United States Producer Durables
Add EXCEL TR INC EXL United States Financial Services
Add EXPRESS INC EXPR United States Consumer Discretionary
Delete FARMERS CAPITAL BK CORP FFKT United States Financial Services
Add FEDERAL AGRIC MTG CO AGM United States Financial Services
Add FEDERAL HOME LN MTG CORP FRE United States Financial Services
Add FIBERTOWER CORP FTWR United States Utilities
Add FINANCIAL ENGINES INC FNGN United States Financial Services
Add FINISAR CORP FNSR United States Technology
Delete FIRST ACCEPTANCE CORP FAC United States Financial Services
Delete FIRST CALIFORNIA FINL GR FCAL United States Financial Services
Delete FIRST DEFIANCE FINANCIAL FDEF United States Financial Services
Delete FIRST FINL NORTHWEST FFNW United States Financial Services
Delete FIRST FINL SVC CORP FFKY United States Financial Services
Add FIRST INTST BANCSYSTEM FIBK United States Financial Services
Add FIVE STAR QUALITY CARE FVE United States Health Care
Delete FRISCHS RESTAURANTS INC FRS United States Consumer Discretionary
Add FSI INTL INC FSII United States Technology
Delete FUQI INTERNATIONAL INC FUQI United States Consumer Discretionary
Delete FUSHI COPPERWELD INC FSIN United States Materials & Processing
Add GASTAR EXPL LTD GST United States Energy
Add GENERAL GROWTH PPTYS INC GGP United States Financial Services
Delete GENERAL STEEL HOLDINGS GSI United States Materials & Processing
Delete GEOKINETICS INC GOK United States Energy
Add GEORGIA GULF CORP GGC United States Materials & Processing
Add GERBER SCIENTIFIC INC GRB United States Producer Durables
Add GERDAU AMERISTEEL CORP GNA United States Materials & Processing
Add GEROVA FINANCIAL GROUP GFC United States Financial Services
Add GLOBAL GEOPHYSICAL SVCS GGS United States Energy
Add GLOBALSTAR INC GSAT United States Utilities
Add GLOBE SPECIALTY METALS GSM United States Materials & Processing
Add GOLDEN STAR RES LTD CDA GSS United States Materials & Processing
Add GOLUB CAP BDC INC GBDC United States Financial Services
Delete GRAMERCY CAPITAL CORP GKK United States Financial Services
Delete GRAN TIERRA ENERGY INC GTE United States Energy
Add GRAY TELEVISION INC GTN United States Consumer Discretionary
Delete GREAT WOLF RESORTS INC WOLF United States Consumer Discretionary
Add GREEN BANKSHARES INC GRNB United States Financial Services
Delete GSE SYS INC GVP United States Technology
Delete GTX INC GTXI United States Health Care
Delete GUARANTY BANCORP GBNK United States Financial Services
Add GUIDANCE SOFTWARE INC GUID United States Technology
Add HALLADOR ENERGY CO HNRG United States Energy
Delete HAMPTON ROADS BANKSHARES HMPR United States Financial Services
Add HANMI FINANCIAL CORP HAFC United States Financial Services
Delete HARBIN ELECTRIC INC HRBN United States Producer Durables
Delete HARVARD BIOSCIENCE INC HBIO United States Health Care
Add HEALTHTRONICS INC HTRN United States Health Care
Delete HEMISPHERX BIOPHARMA INC HEB United States Health Care
Delete HERITAGE CRYL CLEAN INC HCCI United States Producer Durables
Add HFF INC HF United States Financial Services
Delete HICKORY TECH CORP HTCO United States Utilities
Add HOKU CORPORATION HOKU United States Energy
Add HOUSTON AMERICAN ENERGY HUSA United States Energy
Delete HQ SUSTAINABLE MARITIM HQS United States Consumer Staples
Add HUDSON HIGHLAND GROUP HHGP United States Producer Durables
Add HUDSON VALLEY HOLDING HUVL United States Financial Services
Delete HURCO COMPANIES INC HURC United States Producer Durables
Add HUTCHINSON TECHNOLOGY HTCH United States Technology
Add HYPERCOM CORP HYC United States Technology
Add ICO GLOBAL COMM HLDGS ICOG United States Utilities
Delete IDERA PHARMACEUTICALS IDRA United States Health Care
Add IDT CORP IDT United States Utilities
Add IKANOS COMMUNICATIONS IKAN United States Technology
Delete IMERGENT INC IIG United States Technology
Delete INCONTACT INC SAAS United States Utilities
Delete INDEPENDENCE HOLDING CO IHC United States Financial Services
Delete INFORMATION SERVICES GRP III United States Financial Services
Add INGERSOLL-RAND PLC IR United States Producer Durables
Add INHIBITEX INC INHX United States Health Care
Delete INNODATA ISOGEN INC INOD United States Producer Durables
Delete INNOSPEC INC IOSP United States Materials & Processing
Add INOVIO PHARMACEUTICALS INO United States Health Care
Delete INSMED INC INSM United States Health Care
Delete INTEGRATED ELECTRICAL SV IESC United States Producer Durables
Add INTEGRATED SILICON S ISSI United States Technology
Delete IPASS INC IPAS United States Consumer Discretionary
Add IRIDIUM COMMUNICATIONS IRDM United States Utilities
Delete ISTA PHARMACEUTICALS INC ISTA United States Health Care
Delete JACKSON HEWITT TAX SVC JTX United States Consumer Discretionary
Add JAGUAR MNG INC JAG United States Materials & Processing
Add JAMBA INC JMBA United States Consumer Discretionary
Delete JAVELIN PHARMACEUTICALS JAV United States Health Care
Add JAZZ PHARMACEUTICALS INC JAZZ United States Health Care
Add JOES JEANS INC JOEZ United States Consumer Discretionary
Add JOHNSON OUTDOORS INC JOUT United States Consumer Discretionary
Delete K V PHARMACEUTICAL CO KV.A United States Health Care
Add KEITHLEY INSTRS INC KEI United States Producer Durables
Add KENNEDY-WILSON HLDGS INC KW United States Financial Services
Delete KENTUCKY FIRST FEDERAL KFFB United States Financial Services
Add KERYX BIOPHARMACEUTICALS KERX United States Health Care
Add KID BRANDS INC KID United States Consumer Discretionary
Add KIT DIGITAL INC KITD United States Technology
Add KMG CHEMICALS INC KMGB United States Materials & Processing
Add KODIAK OIL & GAS CORP KOG United States Energy
Delete KOHLBERG CAPITAL CORP KCAP United States Financial Services
Add KRATOS DEFENSE & SEC SOL KTOS United States Producer Durables
Add L & L ENERGY INC LLEN United States Energy
Add LACROSSE FOOTWEAR INC BOOT United States Consumer Discretionary
Add LADENBURG THALMAN FIN LTS United States Financial Services
Delete LAKES ENTERTAINMENT INC LACO United States Consumer Discretionary
Add LEAR CORP LEA United States Consumer Discretionary
Add LECG CORP XPRT United States Producer Durables
Add LEE ENTERPRISES INC LEE United States Consumer Discretionary
Delete LEGACY BANCORP INC LEGC United States Financial Services
Add LIBBEY INC LBY United States Consumer Discretionary
Add LIFETIME BRANDS INC LCUT United States Consumer Discretionary
Delete LIHUA INTERNATIONAL INC LIWA United States Producer Durables
Add LIMONEIRA CO LMNR United States Consumer Staples
Add LIONS GATE ENTMNT CORP LGF United States Consumer Discretionary
Add LOCAL COM CORP LOCM United States Technology
Add LTX-CREDENCE CORP LTXC United States Technology
Delete LUBYS INC LUB United States Consumer Discretionary
Delete LULULEMON ATHLETICA INC LULU United States Consumer Discretionary
Add LYDALL INC LDL United States Producer Durables
Add MAGMA DESIGN AUTOMATION LAVA United States Technology
Add MAGNUM HUNTER RES CORP MHR United States Energy
Delete MANNATECH INC MTEX United States Consumer Staples
Add MARINEMAX INC HZO United States Consumer Discretionary
Add MARLIN BUSINESS SVCS MRLN United States Producer Durables
Delete MATRIXX INITIATIVES INC MTXX United States Health Care
Add MATTSON TECHNOLOGY INC MTSN United States Technology
Add MAXLINEAR INC MXL United States Technology
Add MCCLATCHY CO MNI United States Consumer Discretionary
Add MEDIA GENERAL INC MEG United States Consumer Discretionary
Delete MEMSIC INC MEMS United States Technology
Delete MERCADOLIBRE INC MELI United States Consumer Discretionary
Delete MERCER INS GROUP INC MIGP United States Financial Services
Add MERU NETWORKS INC MERU United States Technology
Add METALS USA HLDGS CORP MUSA United States Materials & Processing
Add MGP INGREDIENTS INC MGPI United States Consumer Staples
Add MIDWESTONE FINL GROUP MOFG United States Financial Services
Add MILLER PETE INC MILL United States Energy
Add MINDSPEED TECHNOLOGIES MSPD United States Technology
Delete MOLECULAR INSIGHT PHARMA MIPI United States Health Care
Add MOSYS INC MOSY United States Technology
Add MPG OFFICE TRUST INC MPG United States Financial Services
Delete MYRIAD PHARMA INC MYRX United States Health Care
Add NANOMETRICS INC NANO United States Technology
Add NATIONAL AMERN UNIV NAUH United States Consumer Discretionary
Add NATURES SUNSHINE PRODS NATR United States Consumer Staples
Add NEOSTEM INC NBS United States Health Care
Delete NESS TECHNOLOGIES INC NSTC United States Technology
Delete NET 1 UEPS TECHNOLOGIES UEPS United States Financial Services
Add NETWORK ENGINES INC NENG United States Technology
Add NEURALSTEM INC CUR United States Health Care
Add NEWCASTLE INVT CORP NCT United States Financial Services
Add NEXSTAR BROADCASTING GRP NXST United States Consumer Discretionary
Delete NIGHTHAWK RADIOLOGY HLDG NHWK United States Health Care
Delete NIVS INTELLIMEDIA TECH NIV United States Consumer Discretionary
Delete NOBEL LEARNING CMNTYS NLCI United States Consumer Discretionary
Add NORANDA ALUM HLDG CORP NOR United States Materials & Processing
Delete NORTHEAST CMNTY BANCORP NECB United States Financial Services
Delete NORTHRIM BANCORP INC NRIM United States Financial Services
Delete NORWOOD FINANCIAL CORP NWFL United States Financial Services
Delete NOVAMED INC NOVAD United States Health Care
Add OCCAM NETWORKS INC OCNW United States Technology
Add OCLARO INC OCLR United States Technology
Delete ODYSSEY MARINE EXPLOR OMEX United States Producer Durables
Delete OHIO VY BANC CORP OVBC United States Financial Services
Delete OILSANDS QUEST INC BQI United States Energy
Delete OLD POINT FINL CORP OPOF United States Financial Services
Delete OLD SECOND BANCORP INC OSBC United States Financial Services
Delete OMEGA PROTEIN CORP OME United States Consumer Staples
Delete ONCOGENEX PHARMAS INC OGXI United States Health Care
Add ONE LIBERTY PROPERTIES OLP United States Financial Services
Delete ORCHIDS PAPER PRODS COMP TIS United States Consumer Staples
Delete ORION ENERGY SYSTEMS INC OESX United States Materials & Processing
Delete OVERHILL FARMS INC OFI United States Consumer Staples
Delete OXIGENE INC OXGN United States Health Care
Add P A M TRANSN SVCS INC PTSI United States Producer Durables
Delete PACIFIC CAPITAL BANCORP PCBC United States Financial Services
Delete PAR TECHNOLOGY CORP PTC United States Technology
Delete PARAMOUNT GOLD & SILVER PZG United States Materials & Processing
Add PARK OHIO HOLDINGS CORP PKOH United States Producer Durables
Delete PARKERVISION INC PRKR United States Technology
Delete PC MALL INC MALL United States Technology
Add PDF SOLUTIONS INC PDFS United States Technology
Add PDI INC PDII United States Producer Durables
Delete PENNICHUCK CORP PNNW United States Utilities
Delete PEOPLES FINL CORP MISS PFBX United States Financial Services
Add PEREGRINE PHARMA INC PPHM United States Health Care
Delete PERMA-FIX ENVIRONMENTAL PESI United States Producer Durables
Delete PERVASIVE SOFTWARE INC PVSW United States Technology
Add PGT INC PGTI United States Materials & Processing
Add PHARMACYCLICS INC PCYC United States Health Care
Delete PHOENIX TECHNOLOGIES LTD PTEC United States Technology
Add PILGRIMS PRIDE CORP NEW PPC United States Consumer Staples
Add PINNACLE AIRL CORP PNCL United States Producer Durables
Delete PONIARD PHARMA INC PARD United States Health Care
Delete PORTEC RAIL PRODUCTS INC PRPX United States Producer Durables
Delete PREMIERWEST BANCORP PRWT United States Financial Services
Add PRESSTEK INC PRST United States Producer Durables
Delete PRIMEENERGY CORP PNRG United States Energy
Add PRIMERICA INC PRI United States Financial Services
Add PROSPECT MEDICAL HLDGS PZZ United States Health Care
Delete PROTALIX BIOTHERAPEUTICS PLX United States Health Care
Delete PRUDENTIAL BANCORP INC PBIP United States Financial Services
Add PURE BIOSCIENCE PURE United States Health Care
Delete QC HOLDINGS INC QCCO United States Financial Services
Add QUALITY DISTRIBUTION INC QLTY United States Producer Durables
Add RADIO ONE INC ROIAK United States Consumer Discretionary
Delete RADNET INC RDNT United States Health Care
Delete RAE SYSTEMS INC RAE United States Producer Durables
Add RAM ENERGY RESOURCES INC RAME United States Energy
Delete RASER TECHNOLOGIES INC RZ United States Energy
Add REACHLOCAL INC RLOC United States Consumer Discretionary
Delete READING INTERNATIONAL RDI United States Consumer Discretionary
Add RENTECH INC RTK United States Materials & Processing
Delete REPLIGEN CORP RGEN United States Health Care
Delete REPROS THERAPEUTICS INC RPRX United States Health Care
Delete REPUBLIC FIRST BANCORP FRBK United States Financial Services
Add RESOLUTE ENERGY CORP REN United States Energy
Delete RESOURCE AMERICA INC REXI United States Financial Services
Add RETAIL OPPORTUNITY INVTS ROIC United States Financial Services
Delete REWARDS NETWORK INC DINE United States Financial Services
Add RICHARDSON ELECTRONICS RELL United States Technology
Add ROADRUNNER TRNSN SVCS RRTS United States Producer Durables
Delete ROCKWELL MEDICAL TECH RMTI United States Health Care
Add RODMAN & RENSHAW CAP GP RODM United States Financial Services
Add RURAL/METRO CORP RURL United States Health Care
Add SANFILIPPO JOHN B & SON JBSS United States Consumer Staples
Add SANMINA SCI CORP SANM United States Technology
Add SCORPIO TANKERS INC STNG United States Producer Durables
Add SELECT COMFORT CORP SCSS United States Consumer Discretionary
Add SENOMYX INC SNMX United States Materials & Processing
Add SENORX INC SENO United States Health Care
Delete SHENGDA TECH INC SDTH United States Materials & Processing
Add SHILOH INDUSTRIES INC SHLO United States Materials & Processing
Delete SHORE BANCSHARES INC SHBI United States Financial Services
Add SIRIUS XM RADIO INC SIRI United States Consumer Discretionary
Delete SMARTHEAT INC HEAT United States Producer Durables
Delete SMITHTOWN BANCORP INC SMTB United States Financial Services
Delete SOHU COM INC SOHU United States Technology
Add SOLTA MEDICAL INC SLTM United States Health Care
Add SOMAXON PHARMACEUTICALS SOMX United States Health Care
Add SONIC SOLUTIONS SNIC United States Technology
Delete SOUTH FINANCIAL GROUP TSFG United States Financial Services
Add SPANSION INC CODE United States Technology
Add SPECTRUM BRANDS INC SPB United States Consumer Staples
Add SPS COMM INC SPSC United States Technology
Add SS&C TECHNOLOGIES HLDGS SSNC United States Technology
Add STAAR SURGICAL CO STAA United States Health Care
Delete STANLEY FURNITURE CO INC STLY United States Consumer Discretionary
Delete STARTEK INC SRT United States Producer Durables
Delete STERLING FINL CORP WA STSA United States Financial Services
Add STREAM GLOBAL SVCS INC SGS United States Producer Durables
Delete SULPHCO INC SUF United States Energy
Add SUMMER INFANT INC SUMR United States Consumer Discretionary
Delete SUN BANCORP INC NJ SNBC United States Financial Services
Add SUPERMEDIA INC SPMD United States Consumer Discretionary
Delete SUREWEST COMMUNICATIONS SURW United States Utilities
Delete SUTOR TECH GROUP LTD SUTR United States Materials & Processing
Add SXC HEALTH SOLUTIONS SXCI United States Health Care
Delete SYMS CORP SYMS United States Consumer Discretionary
Add SYNERON MEDICAL LTD ELOS United States Health Care
Add TARGACEPT INC TRGT United States Health Care
Add TAYLOR CAPITAL GROUP INC TAYC United States Financial Services
Add TELENAV INC TNAV United States Technology
Add TESCO CORP TESO United States Energy
Add TESSCO TECHNOLOGIES INC TESS United States Technology
Delete TGC INDUSTRIES INC TGE United States Energy
Add THERMADYNE HLDGS CORP THMD United States Producer Durables
Add THL CR INC TCRD United States Financial Services
Add THOMAS PROPERTIES GROUP TPGI United States Financial Services
Add THOMPSON CREEK METALS TC United States Materials & Processing
Add THOMSON REUTERS CORP TRI United States Financial Services
Delete TODD SHIPYARDS CORP TOD United States Producer Durables
Delete TOREADOR RESOURCES CORP TRGL United States Energy
Delete TOWN SPORTS INTL CLUB United States Consumer Discretionary
Add TPC GROUP INC TPCG United States Materials & Processing
Delete TRANS1 INC TSON United States Health Care
Add TRANSATLANTIC PETROLEUM TAT United States Energy
Add TRANSCEPT PHARM INC TSPT United States Health Care
Delete TRANSCONTINENTAL REALTY TCI United States Financial Services
Delete TREE.COM INC TREE United States Financial Services
Add TWO HBRS INVT CORP TWO United States Financial Services
Add TYCO INTERNATIONAL LTD TYC United States Producer Durables
Add U S ENERGY CORP USEG United States Materials & Processing
Delete U S GEOTHERMAL INC HTM United States Energy
Delete U S GLOBAL INVS INC GROW United States Financial Services
Add ULTRA CLEAN HOLDINGS INC UCTT United States Technology
Add ULTRA PETROLEUM CORP UPL United States Energy
Delete ULTRALIFE CORPORATION ULBI United States Producer Durables
Add UNILIFE CORP NEW UNIS United States Health Care
Delete UNITED SECURITY BANC INC USBI United States Financial Services
Delete UNIVERSAL TRAVEL GROUP UTA United States Consumer Discretionary
Add UQM TECHNOLOGIES INC UQM United States Producer Durables
Delete URANERZ ENERGY CORP URZ United States Materials & Processing
Delete UTAH MED PRODS INC UTMD United States Health Care
Delete VALENCE TECHNOLOGY INC VLNC United States Producer Durables
Delete VALHI INC VHI United States Materials & Processing
Add VERSO PAPER CORP VRS United States Materials & Processing
Add VIASYSTEMS GROUP INC VIAS United States Technology
Add VIRGINIA COMM BANCORP VCBI United States Financial Services
Add VIRNETX HOLDING CORP VHC United States Technology
Add VISTAPRINT N V VPRT United States Consumer Discretionary
Add VONAGE HLDGS CORP VG United States Utilities
Add WABASH NATIONAL CORP WNC United States Producer Durables
Add WARNER CHILCOTT PLC WCRX United States Health Care
Add WAVE SYSTEMS CORP WAVX United States Technology
Add WEATHERFORD INTL WFT United States Energy
Delete WEB.COM GROUP INC WWWW United States Technology
Add WEST COAST BANCORP WCBO United States Financial Services
Delete WESTMORELAND COAL CO WLB United States Energy
Add WESTWOOD ONE INC WWON United States Consumer Discretionary
Delete WILBER CORP GIW United States Financial Services
Delete WILLIS LEASE FINANCE WLFC United States Producer Durables
Add WINMARK CORP WINA United States Consumer Discretionary
Delete WONDER AUTO TECH INC WATG United States Consumer Discretionary
Add XERIUM TECHNOLOGIES INC XRM United States Producer Durables
Add XYRATEX LTD XRTX United States Technology
Delete YADKIN VALLEY FINL CORP YAVY United States Financial Services
Delete YRC WORLDWIDE INC YRCW United States Producer Durables
Delete ZALE CORP ZLC United States Consumer Discretionary
Delete ZHONGPIN INC HOGS United States Consumer Staples
Delete ZION OIL & GAS INC ZN United States Energy
Add ZIOPHARM ONCOLOGY INC ZIOP United States Health Care
Preliminary additions and deletions (Russell 3000® Index)
Russell Reconstitution
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Annual rebalancing of Russell Indexes
In order to maintain true representation of global equity markets and avoid capitalization and style slippage, Russell annually rebalances the entire Russell family of indexes.
Annual reconstitution ensures that the Indexes reflect the changes in the market over time and accurately represent the true opportunity set of institutional managers. Russell's U.S. and global index families reconstitute simultaneously.
2010 Reconstitution
The 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010.
View preliminary additions and deletions to the Russell Indexes
http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx
Updated June 11, 2010
Frequently asked questions
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Reconstitution schedule
June 11
Preliminary additions and deletions to the Russell Global Index, Russell 3000® and Russell Microcap® published after 3:00 p.m. PST
June 18
Updates to the list of additions and deletions
June 25
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
June 28
Final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap Indexes
#############################################################################################
Preliminary additions and deletions (Russell 3000® Index)
As of June 11, 2010
466 changes
Change Company Symbol Country Sector
Add 1ST UNITED BANCORP INC FUBC United States Financial Services
Add A H BELO CORP AHC United States Consumer Discretionary
Add ABRAXAS PETE CORP AXAS United States Energy
Add ACCENTURE PLC IRELAND ACN United States Producer Durables
Add ACCRETIVE HEALTH INC AH United States Health Care
Add ACE LTD ACE United States Financial Services
Delete ACTIVIDENTITY CORP ACTI United States Technology
Delete ADOLOR CORP ADLR United States Health Care
Delete AGFEED INDUSTRIES INC FEED United States Consumer Staples
Add ALCON INC ACL United States Health Care
Add ALEXZA PHARMACEUTICALS ALXA United States Health Care
Add ALIMERA SCIENCES INC ALIM United States Health Care
Add ALPHA & OMEGA SEMICON AOSL United States Technology
Delete AMERICAN CARESOURCE HLDG ANCI United States Health Care
Delete AMERICAN DAIRY INC ADY United States Consumer Staples
Add AMERICAN DG ENERGY INC ADGE United States Utilities
Add AMERICAN OIL & GAS INC AEZ United States Energy
Delete AMERICAN ORIENTAL BIOENG AOB United States Health Care
Delete AMERICAN REALTY INVESTOR ARL United States Financial Services
Delete AMICUS THERAPEUTICS INC FOLD United States Health Care
Delete AMPAL AMERICAN ISRAEL AMPL United States Financial Services
Delete AMREP CORP AXR United States Consumer Discretionary
Add ANTARES PHARMA INC AIS United States Health Care
Add ANTHERA PHARMACEUTICALS ANTH United States Health Care
Add AOXING PHARMACEUTICAL CO AXN United States Health Care
Add APPLIED ENERGETICS INC AERG United States Producer Durables
Add ARCTIC CAT INC ACAT United States Consumer Discretionary
Add ARLINGTON ASSET INVT AI United States Financial Services
Add ARTHROCARE CORP ARTC United States Health Care
Delete ARYX THERAPEUTICS INC ARYX United States Health Care
Delete ASCENT SOLAR TECH INC ASTI United States Energy
Delete ASIAINFO HOLDINGS INC ASIA United States Technology
Add ASPEN TECHNOLOGY INC AZPN United States Technology
Add ASPENBIO PHARMA INC APPY United States Health Care
Add ASTA FDG INC ASFI United States Financial Services
Delete AUBURN NATL BANCORP AUBN United States Financial Services
Add AVAGO TECHNOLOGIES LTD AVGO United States Technology
Add AVEO PHARMACEUTICALS INC AVEO United States Health Care
Add AXCELIS TECHNOLOGIES INC ACLS United States Technology
Add AXT INC AXTI United States Technology
Add BALLANTYNE STRONG INC BTN United States Producer Durables
Add BALTIC TRADING LIMITED BALT United States Producer Durables
Delete BANK KY FINL CORP BKYF United States Financial Services
Delete BANNER CORP BANR United States Financial Services
Delete BAR HBR BANKSHARES BHB United States Financial Services
Add BARRY R G CORP OHIO DFZ United States Consumer Discretionary
Add BEASLEY BROADCAST GROUP BBGI United States Consumer Discretionary
Add BELL MICROPRODUCTS INC BELM United States Technology
Delete BENIHANA INC BNHNA United States Consumer Discretionary
Add BERKSHIRE HATHAWAY INC BRK.B United States Financial Services
Delete BIODELIVERY SCIENCES BDSI United States Health Care
Add BIOSANTE PHARMACEUTICALS BPAX United States Health Care
Add BIOTIME INC BTIM United States Health Care
Add BOFI HLDG INC BOFI United States Financial Services
Delete BOLT TECHNOLOGY CORP BOLT United States Energy
Add BON-TON STORES INC BONT United States Consumer Discretionary
Delete BOVIE MEDICAL CORP BVX United States Health Care
Add BRIDGFORD FOODS CORP BRID United States Consumer Staples
Delete BRONCO DRILLING CO INC BRNC United States Energy
Delete BROOKLYN FEDERAL BANCORP BFSB United States Financial Services
Add CALIPER LIFE SCIENCES CALP United States Health Care
Add CALIX INC CALX United States Technology
Delete CALLIDUS SOFTWARE INC CALD United States Technology
Add CALLON PETROLEUM CO CPE United States Energy
Add CAMAC ENERGY INC CAK United States Energy
Add CAMBIUM LEARNING GRP INC ABCD United States Consumer Discretionary
Delete CAPE BANCORP INC CBNJ United States Financial Services
Add CAPITAL GOLD CORP CGC United States Materials & Processing
Add CAPSTONE TURBINE CORP CPST United States Energy
Delete CARDIAC SCIENCE CORP CSCX United States Health Care
Delete CARDIOVASCULAR SYS INC CSII United States Health Care
Delete CARDIUM THERAPEUTICS INC CXM United States Health Care
Add CASELLA WASTE SYSTEMS CWST United States Consumer Discretionary
Add CASUAL MALE RETAIL GROUP CMRG United States Consumer Discretionary
Add CDC CORP CHINA United States Technology
Delete CELL THERAPEUTICS INC CTIC United States Health Care
Delete CENTER BANCORP INC CNBC United States Financial Services
Add CENTER FINANCIAL CORP CLFC United States Financial Services
Delete CENTRAL PACIFIC FINL CPF United States Financial Services
Add CERUS CORP CERS United States Health Care
Delete CHASE CORP CCF United States Materials & Processing
Add CHATHAM LODGING TR CLDT United States Financial Services
Delete CHEVIOT FINANCIAL CORP CHEV United States Financial Services
Add CHICAGO BRIDGE & IRON CBI United States Producer Durables
Delete CHICOPEE BANCORP INC CBNK United States Financial Services
Delete CHINA AUTOMOTIVE SYSTEMS CAAS United States Consumer Discretionary
Delete CHINA BAK BATTERY INC CBAK United States Producer Durables
Delete CHINA FIRE & SEC GROUP CFSG United States Producer Durables
Delete CHINA GREEN AGRICULTURE CGA United States Consumer Staples
Delete CHINA HOUSING & LAND DEV CHLN United States Financial Services
Delete CHINA INFORMATION SEC CPBY United States Technology
Delete CHINA PRECISION STEEL CPSL United States Materials & Processing
Delete CHINA SEC & SURVE TECH CSR United States Producer Durables
Delete CHINA SKY ONE MED INC CSKI United States Health Care
Delete CHINA TRANSINFO TECHNLGY CTFO United States Technology
Delete CHINA-BIOTICS INC CHBT United States Consumer Staples
Delete CHINACAST EDU CORP CAST United States Consumer Discretionary
Add CIT GROUP INC CIT United States Financial Services
Delete CITIZENS HLDG CO MISS CIZN United States Financial Services
Add CNH GLOBAL N V CNH United States Producer Durables
Add CODEXIS INC CDXS United States Health Care
Delete COGO GROUP INC COGO United States Technology
Add COLEMAN CABLE INC CCIX United States Producer Durables
Add COMBINATORX INC CRXX United States Health Care
Add COMMERCIAL VEH GROUP INC CVGI United States Producer Durables
Delete COMMUNICATIONS SYSTEMS JCS United States Technology
Add COMPX INTERNATIONAL CIX United States Materials & Processing
Add CONEXANT SYSTEMS INC CNXT United States Technology
Add CONVIO INC CNVO United States Technology
Add COOPER INDUSTRIES PLC CBE United States Producer Durables
Add CORCEPT THERAPEUTICS INC CORT United States Health Care
Add CORE LABORATORIES N V CLB United States Energy
Add COVIDIEN PLC COV United States Health Care
Delete CREDO PETROLEUM CORP CRED United States Energy
Delete CTC MEDIA INC CTCM United States Consumer Discretionary
Delete CUBIC ENERGY INC QBC United States Energy
Add CULP INC CFI United States Materials & Processing
Add CUMULUS MEDIA INC CMLS United States Consumer Discretionary
Add CYTRX CORP CYTR United States Health Care
Add DELTA APPAREL INC DLA United States Consumer Discretionary
Add DEX ONE CORP DEXO United States Consumer Discretionary
Add DIGIMARC CORPORATION DMRC United States Technology
Add DISCOVERY COMMUNICATIONS DISCA United States Consumer Discretionary
Delete DISCOVERY COMMUNICATIONS DISCK United States Consumer Discretionary
Delete DISCOVERY LABORATORIES DSCO United States Health Care
Add DOUGLAS DYNAMICS INC PLOW United States Producer Durables
Delete DOVER DOWNS GAMING & ENT DDE United States Consumer Discretionary
Delete DUOYUAN PRINTING INC DYP United States Producer Durables
Delete DYNAMICS RESEARCH CORP DRCO United States Technology
Add DYNAVAX TECHNOLOGIES DVAX United States Health Care
Add DYNAVOX INC DVOX United States Technology
Delete EASTERN CO EML United States Materials & Processing
Delete EASTERN INSURANCE HLDGS EIHI United States Financial Services
Delete ELOYALTY CORP ELOY United States Technology
Delete EMCORE CORP EMKR United States Technology
Add EMPIRE RESORTS INC NYNY United States Consumer Discretionary
Add ENCORE BANCSHARES INC EBTX United States Financial Services
Add ENERGY PARTNERS LTD EPL United States Energy
Add ENERGY XXI (BERMUDA) LTD EXXI United States Energy
Delete ENGLOBAL CORP ENG United States Producer Durables
Add ENTERCOM COMMUNICATIONS ETM United States Consumer Discretionary
Delete ENTEROMEDICS INC ETRM United States Health Care
Delete ENTERPRISE BANCORP INC EBTC United States Financial Services
Add ENTRAVISION COMM EVC United States Consumer Discretionary
Add EURAND N V EURX United States Health Care
Delete EVERGREEN ENERGY INC EEE United States Energy
Add EVOLUTION PETROLEUM CORP EPM United States Energy
Add EXACT SCIENCES CORP EXAS United States Health Care
Add EXCEL MARITIME CARRIERS EXM United States Producer Durables
Add EXCEL TR INC EXL United States Financial Services
Add EXPRESS INC EXPR United States Consumer Discretionary
Delete FARMERS CAPITAL BK CORP FFKT United States Financial Services
Add FEDERAL AGRIC MTG CO AGM United States Financial Services
Add FEDERAL HOME LN MTG CORP FRE United States Financial Services
Add FIBERTOWER CORP FTWR United States Utilities
Add FINANCIAL ENGINES INC FNGN United States Financial Services
Add FINISAR CORP FNSR United States Technology
Delete FIRST ACCEPTANCE CORP FAC United States Financial Services
Delete FIRST CALIFORNIA FINL GR FCAL United States Financial Services
Delete FIRST DEFIANCE FINANCIAL FDEF United States Financial Services
Delete FIRST FINL NORTHWEST FFNW United States Financial Services
Delete FIRST FINL SVC CORP FFKY United States Financial Services
Add FIRST INTST BANCSYSTEM FIBK United States Financial Services
Add FIVE STAR QUALITY CARE FVE United States Health Care
Delete FRISCHS RESTAURANTS INC FRS United States Consumer Discretionary
Add FSI INTL INC FSII United States Technology
Delete FUQI INTERNATIONAL INC FUQI United States Consumer Discretionary
Delete FUSHI COPPERWELD INC FSIN United States Materials & Processing
Add GASTAR EXPL LTD GST United States Energy
Add GENERAL GROWTH PPTYS INC GGP United States Financial Services
Delete GENERAL STEEL HOLDINGS GSI United States Materials & Processing
Delete GEOKINETICS INC GOK United States Energy
Add GEORGIA GULF CORP GGC United States Materials & Processing
Add GERBER SCIENTIFIC INC GRB United States Producer Durables
Add GERDAU AMERISTEEL CORP GNA United States Materials & Processing
Add GEROVA FINANCIAL GROUP GFC United States Financial Services
Add GLOBAL GEOPHYSICAL SVCS GGS United States Energy
Add GLOBALSTAR INC GSAT United States Utilities
Add GLOBE SPECIALTY METALS GSM United States Materials & Processing
Add GOLDEN STAR RES LTD CDA GSS United States Materials & Processing
Add GOLUB CAP BDC INC GBDC United States Financial Services
Delete GRAMERCY CAPITAL CORP GKK United States Financial Services
Delete GRAN TIERRA ENERGY INC GTE United States Energy
Add GRAY TELEVISION INC GTN United States Consumer Discretionary
Delete GREAT WOLF RESORTS INC WOLF United States Consumer Discretionary
Add GREEN BANKSHARES INC GRNB United States Financial Services
Delete GSE SYS INC GVP United States Technology
Delete GTX INC GTXI United States Health Care
Delete GUARANTY BANCORP GBNK United States Financial Services
Add GUIDANCE SOFTWARE INC GUID United States Technology
Add HALLADOR ENERGY CO HNRG United States Energy
Delete HAMPTON ROADS BANKSHARES HMPR United States Financial Services
Add HANMI FINANCIAL CORP HAFC United States Financial Services
Delete HARBIN ELECTRIC INC HRBN United States Producer Durables
Delete HARVARD BIOSCIENCE INC HBIO United States Health Care
Add HEALTHTRONICS INC HTRN United States Health Care
Delete HEMISPHERX BIOPHARMA INC HEB United States Health Care
Delete HERITAGE CRYL CLEAN INC HCCI United States Producer Durables
Add HFF INC HF United States Financial Services
Delete HICKORY TECH CORP HTCO United States Utilities
Add HOKU CORPORATION HOKU United States Energy
Add HOUSTON AMERICAN ENERGY HUSA United States Energy
Delete HQ SUSTAINABLE MARITIM HQS United States Consumer Staples
Add HUDSON HIGHLAND GROUP HHGP United States Producer Durables
Add HUDSON VALLEY HOLDING HUVL United States Financial Services
Delete HURCO COMPANIES INC HURC United States Producer Durables
Add HUTCHINSON TECHNOLOGY HTCH United States Technology
Add HYPERCOM CORP HYC United States Technology
Add ICO GLOBAL COMM HLDGS ICOG United States Utilities
Delete IDERA PHARMACEUTICALS IDRA United States Health Care
Add IDT CORP IDT United States Utilities
Add IKANOS COMMUNICATIONS IKAN United States Technology
Delete IMERGENT INC IIG United States Technology
Delete INCONTACT INC SAAS United States Utilities
Delete INDEPENDENCE HOLDING CO IHC United States Financial Services
Delete INFORMATION SERVICES GRP III United States Financial Services
Add INGERSOLL-RAND PLC IR United States Producer Durables
Add INHIBITEX INC INHX United States Health Care
Delete INNODATA ISOGEN INC INOD United States Producer Durables
Delete INNOSPEC INC IOSP United States Materials & Processing
Add INOVIO PHARMACEUTICALS INO United States Health Care
Delete INSMED INC INSM United States Health Care
Delete INTEGRATED ELECTRICAL SV IESC United States Producer Durables
Add INTEGRATED SILICON S ISSI United States Technology
Delete IPASS INC IPAS United States Consumer Discretionary
Add IRIDIUM COMMUNICATIONS IRDM United States Utilities
Delete ISTA PHARMACEUTICALS INC ISTA United States Health Care
Delete JACKSON HEWITT TAX SVC JTX United States Consumer Discretionary
Add JAGUAR MNG INC JAG United States Materials & Processing
Add JAMBA INC JMBA United States Consumer Discretionary
Delete JAVELIN PHARMACEUTICALS JAV United States Health Care
Add JAZZ PHARMACEUTICALS INC JAZZ United States Health Care
Add JOES JEANS INC JOEZ United States Consumer Discretionary
Add JOHNSON OUTDOORS INC JOUT United States Consumer Discretionary
Delete K V PHARMACEUTICAL CO KV.A United States Health Care
Add KEITHLEY INSTRS INC KEI United States Producer Durables
Add KENNEDY-WILSON HLDGS INC KW United States Financial Services
Delete KENTUCKY FIRST FEDERAL KFFB United States Financial Services
Add KERYX BIOPHARMACEUTICALS KERX United States Health Care
Add KID BRANDS INC KID United States Consumer Discretionary
Add KIT DIGITAL INC KITD United States Technology
Add KMG CHEMICALS INC KMGB United States Materials & Processing
Add KODIAK OIL & GAS CORP KOG United States Energy
Delete KOHLBERG CAPITAL CORP KCAP United States Financial Services
Add KRATOS DEFENSE & SEC SOL KTOS United States Producer Durables
Add L & L ENERGY INC LLEN United States Energy
Add LACROSSE FOOTWEAR INC BOOT United States Consumer Discretionary
Add LADENBURG THALMAN FIN LTS United States Financial Services
Delete LAKES ENTERTAINMENT INC LACO United States Consumer Discretionary
Add LEAR CORP LEA United States Consumer Discretionary
Add LECG CORP XPRT United States Producer Durables
Add LEE ENTERPRISES INC LEE United States Consumer Discretionary
Delete LEGACY BANCORP INC LEGC United States Financial Services
Add LIBBEY INC LBY United States Consumer Discretionary
Add LIFETIME BRANDS INC LCUT United States Consumer Discretionary
Delete LIHUA INTERNATIONAL INC LIWA United States Producer Durables
Add LIMONEIRA CO LMNR United States Consumer Staples
Add LIONS GATE ENTMNT CORP LGF United States Consumer Discretionary
Add LOCAL COM CORP LOCM United States Technology
Add LTX-CREDENCE CORP LTXC United States Technology
Delete LUBYS INC LUB United States Consumer Discretionary
Delete LULULEMON ATHLETICA INC LULU United States Consumer Discretionary
Add LYDALL INC LDL United States Producer Durables
Add MAGMA DESIGN AUTOMATION LAVA United States Technology
Add MAGNUM HUNTER RES CORP MHR United States Energy
Delete MANNATECH INC MTEX United States Consumer Staples
Add MARINEMAX INC HZO United States Consumer Discretionary
Add MARLIN BUSINESS SVCS MRLN United States Producer Durables
Delete MATRIXX INITIATIVES INC MTXX United States Health Care
Add MATTSON TECHNOLOGY INC MTSN United States Technology
Add MAXLINEAR INC MXL United States Technology
Add MCCLATCHY CO MNI United States Consumer Discretionary
Add MEDIA GENERAL INC MEG United States Consumer Discretionary
Delete MEMSIC INC MEMS United States Technology
Delete MERCADOLIBRE INC MELI United States Consumer Discretionary
Delete MERCER INS GROUP INC MIGP United States Financial Services
Add MERU NETWORKS INC MERU United States Technology
Add METALS USA HLDGS CORP MUSA United States Materials & Processing
Add MGP INGREDIENTS INC MGPI United States Consumer Staples
Add MIDWESTONE FINL GROUP MOFG United States Financial Services
Add MILLER PETE INC MILL United States Energy
Add MINDSPEED TECHNOLOGIES MSPD United States Technology
Delete MOLECULAR INSIGHT PHARMA MIPI United States Health Care
Add MOSYS INC MOSY United States Technology
Add MPG OFFICE TRUST INC MPG United States Financial Services
Delete MYRIAD PHARMA INC MYRX United States Health Care
Add NANOMETRICS INC NANO United States Technology
Add NATIONAL AMERN UNIV NAUH United States Consumer Discretionary
Add NATURES SUNSHINE PRODS NATR United States Consumer Staples
Add NEOSTEM INC NBS United States Health Care
Delete NESS TECHNOLOGIES INC NSTC United States Technology
Delete NET 1 UEPS TECHNOLOGIES UEPS United States Financial Services
Add NETWORK ENGINES INC NENG United States Technology
Add NEURALSTEM INC CUR United States Health Care
Add NEWCASTLE INVT CORP NCT United States Financial Services
Add NEXSTAR BROADCASTING GRP NXST United States Consumer Discretionary
Delete NIGHTHAWK RADIOLOGY HLDG NHWK United States Health Care
Delete NIVS INTELLIMEDIA TECH NIV United States Consumer Discretionary
Delete NOBEL LEARNING CMNTYS NLCI United States Consumer Discretionary
Add NORANDA ALUM HLDG CORP NOR United States Materials & Processing
Delete NORTHEAST CMNTY BANCORP NECB United States Financial Services
Delete NORTHRIM BANCORP INC NRIM United States Financial Services
Delete NORWOOD FINANCIAL CORP NWFL United States Financial Services
Delete NOVAMED INC NOVAD United States Health Care
Add OCCAM NETWORKS INC OCNW United States Technology
Add OCLARO INC OCLR United States Technology
Delete ODYSSEY MARINE EXPLOR OMEX United States Producer Durables
Delete OHIO VY BANC CORP OVBC United States Financial Services
Delete OILSANDS QUEST INC BQI United States Energy
Delete OLD POINT FINL CORP OPOF United States Financial Services
Delete OLD SECOND BANCORP INC OSBC United States Financial Services
Delete OMEGA PROTEIN CORP OME United States Consumer Staples
Delete ONCOGENEX PHARMAS INC OGXI United States Health Care
Add ONE LIBERTY PROPERTIES OLP United States Financial Services
Delete ORCHIDS PAPER PRODS COMP TIS United States Consumer Staples
Delete ORION ENERGY SYSTEMS INC OESX United States Materials & Processing
Delete OVERHILL FARMS INC OFI United States Consumer Staples
Delete OXIGENE INC OXGN United States Health Care
Add P A M TRANSN SVCS INC PTSI United States Producer Durables
Delete PACIFIC CAPITAL BANCORP PCBC United States Financial Services
Delete PAR TECHNOLOGY CORP PTC United States Technology
Delete PARAMOUNT GOLD & SILVER PZG United States Materials & Processing
Add PARK OHIO HOLDINGS CORP PKOH United States Producer Durables
Delete PARKERVISION INC PRKR United States Technology
Delete PC MALL INC MALL United States Technology
Add PDF SOLUTIONS INC PDFS United States Technology
Add PDI INC PDII United States Producer Durables
Delete PENNICHUCK CORP PNNW United States Utilities
Delete PEOPLES FINL CORP MISS PFBX United States Financial Services
Add PEREGRINE PHARMA INC PPHM United States Health Care
Delete PERMA-FIX ENVIRONMENTAL PESI United States Producer Durables
Delete PERVASIVE SOFTWARE INC PVSW United States Technology
Add PGT INC PGTI United States Materials & Processing
Add PHARMACYCLICS INC PCYC United States Health Care
Delete PHOENIX TECHNOLOGIES LTD PTEC United States Technology
Add PILGRIMS PRIDE CORP NEW PPC United States Consumer Staples
Add PINNACLE AIRL CORP PNCL United States Producer Durables
Delete PONIARD PHARMA INC PARD United States Health Care
Delete PORTEC RAIL PRODUCTS INC PRPX United States Producer Durables
Delete PREMIERWEST BANCORP PRWT United States Financial Services
Add PRESSTEK INC PRST United States Producer Durables
Delete PRIMEENERGY CORP PNRG United States Energy
Add PRIMERICA INC PRI United States Financial Services
Add PROSPECT MEDICAL HLDGS PZZ United States Health Care
Delete PROTALIX BIOTHERAPEUTICS PLX United States Health Care
Delete PRUDENTIAL BANCORP INC PBIP United States Financial Services
Add PURE BIOSCIENCE PURE United States Health Care
Delete QC HOLDINGS INC QCCO United States Financial Services
Add QUALITY DISTRIBUTION INC QLTY United States Producer Durables
Add RADIO ONE INC ROIAK United States Consumer Discretionary
Delete RADNET INC RDNT United States Health Care
Delete RAE SYSTEMS INC RAE United States Producer Durables
Add RAM ENERGY RESOURCES INC RAME United States Energy
Delete RASER TECHNOLOGIES INC RZ United States Energy
Add REACHLOCAL INC RLOC United States Consumer Discretionary
Delete READING INTERNATIONAL RDI United States Consumer Discretionary
Add RENTECH INC RTK United States Materials & Processing
Delete REPLIGEN CORP RGEN United States Health Care
Delete REPROS THERAPEUTICS INC RPRX United States Health Care
Delete REPUBLIC FIRST BANCORP FRBK United States Financial Services
Add RESOLUTE ENERGY CORP REN United States Energy
Delete RESOURCE AMERICA INC REXI United States Financial Services
Add RETAIL OPPORTUNITY INVTS ROIC United States Financial Services
Delete REWARDS NETWORK INC DINE United States Financial Services
Add RICHARDSON ELECTRONICS RELL United States Technology
Add ROADRUNNER TRNSN SVCS RRTS United States Producer Durables
Delete ROCKWELL MEDICAL TECH RMTI United States Health Care
Add RODMAN & RENSHAW CAP GP RODM United States Financial Services
Add RURAL/METRO CORP RURL United States Health Care
Add SANFILIPPO JOHN B & SON JBSS United States Consumer Staples
Add SANMINA SCI CORP SANM United States Technology
Add SCORPIO TANKERS INC STNG United States Producer Durables
Add SELECT COMFORT CORP SCSS United States Consumer Discretionary
Add SENOMYX INC SNMX United States Materials & Processing
Add SENORX INC SENO United States Health Care
Delete SHENGDA TECH INC SDTH United States Materials & Processing
Add SHILOH INDUSTRIES INC SHLO United States Materials & Processing
Delete SHORE BANCSHARES INC SHBI United States Financial Services
Add SIRIUS XM RADIO INC SIRI United States Consumer Discretionary
Delete SMARTHEAT INC HEAT United States Producer Durables
Delete SMITHTOWN BANCORP INC SMTB United States Financial Services
Delete SOHU COM INC SOHU United States Technology
Add SOLTA MEDICAL INC SLTM United States Health Care
Add SOMAXON PHARMACEUTICALS SOMX United States Health Care
Add SONIC SOLUTIONS SNIC United States Technology
Delete SOUTH FINANCIAL GROUP TSFG United States Financial Services
Add SPANSION INC CODE United States Technology
Add SPECTRUM BRANDS INC SPB United States Consumer Staples
Add SPS COMM INC SPSC United States Technology
Add SS&C TECHNOLOGIES HLDGS SSNC United States Technology
Add STAAR SURGICAL CO STAA United States Health Care
Delete STANLEY FURNITURE CO INC STLY United States Consumer Discretionary
Delete STARTEK INC SRT United States Producer Durables
Delete STERLING FINL CORP WA STSA United States Financial Services
Add STREAM GLOBAL SVCS INC SGS United States Producer Durables
Delete SULPHCO INC SUF United States Energy
Add SUMMER INFANT INC SUMR United States Consumer Discretionary
Delete SUN BANCORP INC NJ SNBC United States Financial Services
Add SUPERMEDIA INC SPMD United States Consumer Discretionary
Delete SUREWEST COMMUNICATIONS SURW United States Utilities
Delete SUTOR TECH GROUP LTD SUTR United States Materials & Processing
Add SXC HEALTH SOLUTIONS SXCI United States Health Care
Delete SYMS CORP SYMS United States Consumer Discretionary
Add SYNERON MEDICAL LTD ELOS United States Health Care
Add TARGACEPT INC TRGT United States Health Care
Add TAYLOR CAPITAL GROUP INC TAYC United States Financial Services
Add TELENAV INC TNAV United States Technology
Add TESCO CORP TESO United States Energy
Add TESSCO TECHNOLOGIES INC TESS United States Technology
Delete TGC INDUSTRIES INC TGE United States Energy
Add THERMADYNE HLDGS CORP THMD United States Producer Durables
Add THL CR INC TCRD United States Financial Services
Add THOMAS PROPERTIES GROUP TPGI United States Financial Services
Add THOMPSON CREEK METALS TC United States Materials & Processing
Add THOMSON REUTERS CORP TRI United States Financial Services
Delete TODD SHIPYARDS CORP TOD United States Producer Durables
Delete TOREADOR RESOURCES CORP TRGL United States Energy
Delete TOWN SPORTS INTL CLUB United States Consumer Discretionary
Add TPC GROUP INC TPCG United States Materials & Processing
Delete TRANS1 INC TSON United States Health Care
Add TRANSATLANTIC PETROLEUM TAT United States Energy
Add TRANSCEPT PHARM INC TSPT United States Health Care
Delete TRANSCONTINENTAL REALTY TCI United States Financial Services
Delete TREE.COM INC TREE United States Financial Services
Add TWO HBRS INVT CORP TWO United States Financial Services
Add TYCO INTERNATIONAL LTD TYC United States Producer Durables
Add U S ENERGY CORP USEG United States Materials & Processing
Delete U S GEOTHERMAL INC HTM United States Energy
Delete U S GLOBAL INVS INC GROW United States Financial Services
Add ULTRA CLEAN HOLDINGS INC UCTT United States Technology
Add ULTRA PETROLEUM CORP UPL United States Energy
Delete ULTRALIFE CORPORATION ULBI United States Producer Durables
Add UNILIFE CORP NEW UNIS United States Health Care
Delete UNITED SECURITY BANC INC USBI United States Financial Services
Delete UNIVERSAL TRAVEL GROUP UTA United States Consumer Discretionary
Add UQM TECHNOLOGIES INC UQM United States Producer Durables
Delete URANERZ ENERGY CORP URZ United States Materials & Processing
Delete UTAH MED PRODS INC UTMD United States Health Care
Delete VALENCE TECHNOLOGY INC VLNC United States Producer Durables
Delete VALHI INC VHI United States Materials & Processing
Add VERSO PAPER CORP VRS United States Materials & Processing
Add VIASYSTEMS GROUP INC VIAS United States Technology
Add VIRGINIA COMM BANCORP VCBI United States Financial Services
Add VIRNETX HOLDING CORP VHC United States Technology
Add VISTAPRINT N V VPRT United States Consumer Discretionary
Add VONAGE HLDGS CORP VG United States Utilities
Add WABASH NATIONAL CORP WNC United States Producer Durables
Add WARNER CHILCOTT PLC WCRX United States Health Care
Add WAVE SYSTEMS CORP WAVX United States Technology
Add WEATHERFORD INTL WFT United States Energy
Delete WEB.COM GROUP INC WWWW United States Technology
Add WEST COAST BANCORP WCBO United States Financial Services
Delete WESTMORELAND COAL CO WLB United States Energy
Add WESTWOOD ONE INC WWON United States Consumer Discretionary
Delete WILBER CORP GIW United States Financial Services
Delete WILLIS LEASE FINANCE WLFC United States Producer Durables
Add WINMARK CORP WINA United States Consumer Discretionary
Delete WONDER AUTO TECH INC WATG United States Consumer Discretionary
Add XERIUM TECHNOLOGIES INC XRM United States Producer Durables
Add XYRATEX LTD XRTX United States Technology
Delete YADKIN VALLEY FINL CORP YAVY United States Financial Services
Delete YRC WORLDWIDE INC YRCW United States Producer Durables
Delete ZALE CORP ZLC United States Consumer Discretionary
Delete ZHONGPIN INC HOGS United States Consumer Staples
Delete ZION OIL & GAS INC ZN United States Energy
Add ZIOPHARM ONCOLOGY INC ZIOP United States Health Care
Russell Reconstitution // (UNIS)
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Annual rebalancing of Russell Indexes
In order to maintain true representation of global equity markets and avoid capitalization and style slippage, Russell annually rebalances the entire Russell family of indexes.
Annual reconstitution ensures that the Indexes reflect the changes in the market over time and accurately represent the true opportunity set of institutional managers. Russell's U.S. and global index families reconstitute simultaneously.
2010 Reconstitution
The 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010.
View preliminary additions and deletions to the Russell Indexes
http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx
Updated June 11, 2010
Frequently asked questions
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Reconstitution schedule
June 11
Preliminary additions and deletions to the Russell Global Index, Russell 3000® and Russell Microcap® published after 3:00 p.m. PST
June 18
Updates to the list of additions and deletions
June 25
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
June 28
Final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap Indexes
#############################################################################################
Preliminary additions and deletions (Russell 3000® Index)
As of June 11, 2010
...
Add UNILIFE CORP NEW UNIS United States Health Care
Russell Reconstitution // (DSCO)
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Annual rebalancing of Russell Indexes
In order to maintain true representation of global equity markets and avoid capitalization and style slippage, Russell annually rebalances the entire Russell family of indexes.
Annual reconstitution ensures that the Indexes reflect the changes in the market over time and accurately represent the true opportunity set of institutional managers. Russell's U.S. and global index families reconstitute simultaneously.
2010 Reconstitution
The 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010.
View preliminary additions and deletions to the Russell Indexes
http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx
Updated June 11, 2010
Frequently asked questions
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Reconstitution schedule
June 11
Preliminary additions and deletions to the Russell Global Index, Russell 3000® and Russell Microcap® published after 3:00 p.m. PST
June 18
Updates to the list of additions and deletions
June 25
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
June 28
Final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap Indexes
#############################################################################################
Preliminary additions and deletions (Russell 3000® Index)
As of June 11, 2010
...
Delete DISCOVERY LABORATORIES DSCO United States Health Care
Russell Reconstitution // (CXM)
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Annual rebalancing of Russell Indexes
In order to maintain true representation of global equity markets and avoid capitalization and style slippage, Russell annually rebalances the entire Russell family of indexes.
Annual reconstitution ensures that the Indexes reflect the changes in the market over time and accurately represent the true opportunity set of institutional managers. Russell's U.S. and global index families reconstitute simultaneously.
2010 Reconstitution
The 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010.
View preliminary additions and deletions to the Russell Indexes
http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx
Updated June 11, 2010
Frequently asked questions
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Reconstitution schedule
June 11
Preliminary additions and deletions to the Russell Global Index, Russell 3000® and Russell Microcap® published after 3:00 p.m. PST
June 18
Updates to the list of additions and deletions
June 25
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
June 28
Final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap Indexes
#############################################################################################
Preliminary additions and deletions (Russell 3000® Index)
As of June 11, 2010
...
Delete CARDIUM THERAPEUTICS INC CXM United States Health Care
Russell Reconstitution // (KERX)
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Annual rebalancing of Russell Indexes
In order to maintain true representation of global equity markets and avoid capitalization and style slippage, Russell annually rebalances the entire Russell family of indexes.
Annual reconstitution ensures that the Indexes reflect the changes in the market over time and accurately represent the true opportunity set of institutional managers. Russell's U.S. and global index families reconstitute simultaneously.
2010 Reconstitution
The 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010.
View preliminary additions and deletions to the Russell Indexes
http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx
Updated June 11, 2010
Frequently asked questions
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Reconstitution schedule
June 11
Preliminary additions and deletions to the Russell Global Index, Russell 3000® and Russell Microcap® published after 3:00 p.m. PST
June 18
Updates to the list of additions and deletions
June 25
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
June 28
Final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap Indexes
#############################################################################################
Preliminary additions and deletions (Russell 3000® Index)
As of June 11, 2010
...
Add KERYX BIOPHARMACEUTICALS KERX United States Health Care
Russell Reconstitution
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Annual rebalancing of Russell Indexes
In order to maintain true representation of global equity markets and avoid capitalization and style slippage, Russell annually rebalances the entire Russell family of indexes.
Annual reconstitution ensures that the Indexes reflect the changes in the market over time and accurately represent the true opportunity set of institutional managers. Russell's U.S. and global index families reconstitute simultaneously.
2010 Reconstitution
The 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010.
View preliminary additions and deletions to the Russell Indexes
http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx
Updated June 11, 2010
Frequently asked questions
http://www.russell.com/Indexes/membership/Reconstitution/default.asp
Reconstitution schedule
June 11
Preliminary additions and deletions to the Russell Global Index, Russell 3000® and Russell Microcap® published after 3:00 p.m. PST
June 18
Updates to the list of additions and deletions
June 25
Updates to the list of additions and deletions
Reconstitution final after the close of the U.S. markets
June 28
Final membership lists posted for the Russell Global, Russell 3000, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap Indexes
#############################################################################################
Preliminary additions and deletions (Russell 3000® Index)
As of June 11, 2010
466 changes
Change Company Symbol Country Sector
Add 1ST UNITED BANCORP INC FUBC United States Financial Services
Add A H BELO CORP AHC United States Consumer Discretionary
Add ABRAXAS PETE CORP AXAS United States Energy
Add ACCENTURE PLC IRELAND ACN United States Producer Durables
Add ACCRETIVE HEALTH INC AH United States Health Care
Add ACE LTD ACE United States Financial Services
Delete ACTIVIDENTITY CORP ACTI United States Technology
Delete ADOLOR CORP ADLR United States Health Care
Delete AGFEED INDUSTRIES INC FEED United States Consumer Staples
Add ALCON INC ACL United States Health Care
Add ALEXZA PHARMACEUTICALS ALXA United States Health Care
Add ALIMERA SCIENCES INC ALIM United States Health Care
Add ALPHA & OMEGA SEMICON AOSL United States Technology
Delete AMERICAN CARESOURCE HLDG ANCI United States Health Care
Delete AMERICAN DAIRY INC ADY United States Consumer Staples
Add AMERICAN DG ENERGY INC ADGE United States Utilities
Add AMERICAN OIL & GAS INC AEZ United States Energy
Delete AMERICAN ORIENTAL BIOENG AOB United States Health Care
Delete AMERICAN REALTY INVESTOR ARL United States Financial Services
Delete AMICUS THERAPEUTICS INC FOLD United States Health Care
Delete AMPAL AMERICAN ISRAEL AMPL United States Financial Services
Delete AMREP CORP AXR United States Consumer Discretionary
Add ANTARES PHARMA INC AIS United States Health Care
Add ANTHERA PHARMACEUTICALS ANTH United States Health Care
Add AOXING PHARMACEUTICAL CO AXN United States Health Care
Add APPLIED ENERGETICS INC AERG United States Producer Durables
Add ARCTIC CAT INC ACAT United States Consumer Discretionary
Add ARLINGTON ASSET INVT AI United States Financial Services
Add ARTHROCARE CORP ARTC United States Health Care
Delete ARYX THERAPEUTICS INC ARYX United States Health Care
Delete ASCENT SOLAR TECH INC ASTI United States Energy
Delete ASIAINFO HOLDINGS INC ASIA United States Technology
Add ASPEN TECHNOLOGY INC AZPN United States Technology
Add ASPENBIO PHARMA INC APPY United States Health Care
Add ASTA FDG INC ASFI United States Financial Services
Delete AUBURN NATL BANCORP AUBN United States Financial Services
Add AVAGO TECHNOLOGIES LTD AVGO United States Technology
Add AVEO PHARMACEUTICALS INC AVEO United States Health Care
Add AXCELIS TECHNOLOGIES INC ACLS United States Technology
Add AXT INC AXTI United States Technology
Add BALLANTYNE STRONG INC BTN United States Producer Durables
Add BALTIC TRADING LIMITED BALT United States Producer Durables
Delete BANK KY FINL CORP BKYF United States Financial Services
Delete BANNER CORP BANR United States Financial Services
Delete BAR HBR BANKSHARES BHB United States Financial Services
Add BARRY R G CORP OHIO DFZ United States Consumer Discretionary
Add BEASLEY BROADCAST GROUP BBGI United States Consumer Discretionary
Add BELL MICROPRODUCTS INC BELM United States Technology
Delete BENIHANA INC BNHNA United States Consumer Discretionary
Add BERKSHIRE HATHAWAY INC BRK.B United States Financial Services
Delete BIODELIVERY SCIENCES BDSI United States Health Care
Add BIOSANTE PHARMACEUTICALS BPAX United States Health Care
Add BIOTIME INC BTIM United States Health Care
Add BOFI HLDG INC BOFI United States Financial Services
Delete BOLT TECHNOLOGY CORP BOLT United States Energy
Add BON-TON STORES INC BONT United States Consumer Discretionary
Delete BOVIE MEDICAL CORP BVX United States Health Care
Add BRIDGFORD FOODS CORP BRID United States Consumer Staples
Delete BRONCO DRILLING CO INC BRNC United States Energy
Delete BROOKLYN FEDERAL BANCORP BFSB United States Financial Services
Add CALIPER LIFE SCIENCES CALP United States Health Care
Add CALIX INC CALX United States Technology
Delete CALLIDUS SOFTWARE INC CALD United States Technology
Add CALLON PETROLEUM CO CPE United States Energy
Add CAMAC ENERGY INC CAK United States Energy
Add CAMBIUM LEARNING GRP INC ABCD United States Consumer Discretionary
Delete CAPE BANCORP INC CBNJ United States Financial Services
Add CAPITAL GOLD CORP CGC United States Materials & Processing
Add CAPSTONE TURBINE CORP CPST United States Energy
Delete CARDIAC SCIENCE CORP CSCX United States Health Care
Delete CARDIOVASCULAR SYS INC CSII United States Health Care
Delete CARDIUM THERAPEUTICS INC CXM United States Health Care
Add CASELLA WASTE SYSTEMS CWST United States Consumer Discretionary
Add CASUAL MALE RETAIL GROUP CMRG United States Consumer Discretionary
Add CDC CORP CHINA United States Technology
Delete CELL THERAPEUTICS INC CTIC United States Health Care
Delete CENTER BANCORP INC CNBC United States Financial Services
Add CENTER FINANCIAL CORP CLFC United States Financial Services
Delete CENTRAL PACIFIC FINL CPF United States Financial Services
Add CERUS CORP CERS United States Health Care
Delete CHASE CORP CCF United States Materials & Processing
Add CHATHAM LODGING TR CLDT United States Financial Services
Delete CHEVIOT FINANCIAL CORP CHEV United States Financial Services
Add CHICAGO BRIDGE & IRON CBI United States Producer Durables
Delete CHICOPEE BANCORP INC CBNK United States Financial Services
Delete CHINA AUTOMOTIVE SYSTEMS CAAS United States Consumer Discretionary
Delete CHINA BAK BATTERY INC CBAK United States Producer Durables
Delete CHINA FIRE & SEC GROUP CFSG United States Producer Durables
Delete CHINA GREEN AGRICULTURE CGA United States Consumer Staples
Delete CHINA HOUSING & LAND DEV CHLN United States Financial Services
Delete CHINA INFORMATION SEC CPBY United States Technology
Delete CHINA PRECISION STEEL CPSL United States Materials & Processing
Delete CHINA SEC & SURVE TECH CSR United States Producer Durables
Delete CHINA SKY ONE MED INC CSKI United States Health Care
Delete CHINA TRANSINFO TECHNLGY CTFO United States Technology
Delete CHINA-BIOTICS INC CHBT United States Consumer Staples
Delete CHINACAST EDU CORP CAST United States Consumer Discretionary
Add CIT GROUP INC CIT United States Financial Services
Delete CITIZENS HLDG CO MISS CIZN United States Financial Services
Add CNH GLOBAL N V CNH United States Producer Durables
Add CODEXIS INC CDXS United States Health Care
Delete COGO GROUP INC COGO United States Technology
Add COLEMAN CABLE INC CCIX United States Producer Durables
Add COMBINATORX INC CRXX United States Health Care
Add COMMERCIAL VEH GROUP INC CVGI United States Producer Durables
Delete COMMUNICATIONS SYSTEMS JCS United States Technology
Add COMPX INTERNATIONAL CIX United States Materials & Processing
Add CONEXANT SYSTEMS INC CNXT United States Technology
Add CONVIO INC CNVO United States Technology
Add COOPER INDUSTRIES PLC CBE United States Producer Durables
Add CORCEPT THERAPEUTICS INC CORT United States Health Care
Add CORE LABORATORIES N V CLB United States Energy
Add COVIDIEN PLC COV United States Health Care
Delete CREDO PETROLEUM CORP CRED United States Energy
Delete CTC MEDIA INC CTCM United States Consumer Discretionary
Delete CUBIC ENERGY INC QBC United States Energy
Add CULP INC CFI United States Materials & Processing
Add CUMULUS MEDIA INC CMLS United States Consumer Discretionary
Add CYTRX CORP CYTR United States Health Care
Add DELTA APPAREL INC DLA United States Consumer Discretionary
Add DEX ONE CORP DEXO United States Consumer Discretionary
Add DIGIMARC CORPORATION DMRC United States Technology
Add DISCOVERY COMMUNICATIONS DISCA United States Consumer Discretionary
Delete DISCOVERY COMMUNICATIONS DISCK United States Consumer Discretionary
Delete DISCOVERY LABORATORIES DSCO United States Health Care
Add DOUGLAS DYNAMICS INC PLOW United States Producer Durables
Delete DOVER DOWNS GAMING & ENT DDE United States Consumer Discretionary
Delete DUOYUAN PRINTING INC DYP United States Producer Durables
Delete DYNAMICS RESEARCH CORP DRCO United States Technology
Add DYNAVAX TECHNOLOGIES DVAX United States Health Care
Add DYNAVOX INC DVOX United States Technology
Delete EASTERN CO EML United States Materials & Processing
Delete EASTERN INSURANCE HLDGS EIHI United States Financial Services
Delete ELOYALTY CORP ELOY United States Technology
Delete EMCORE CORP EMKR United States Technology
Add EMPIRE RESORTS INC NYNY United States Consumer Discretionary
Add ENCORE BANCSHARES INC EBTX United States Financial Services
Add ENERGY PARTNERS LTD EPL United States Energy
Add ENERGY XXI (BERMUDA) LTD EXXI United States Energy
Delete ENGLOBAL CORP ENG United States Producer Durables
Add ENTERCOM COMMUNICATIONS ETM United States Consumer Discretionary
Delete ENTEROMEDICS INC ETRM United States Health Care
Delete ENTERPRISE BANCORP INC EBTC United States Financial Services
Add ENTRAVISION COMM EVC United States Consumer Discretionary
Add EURAND N V EURX United States Health Care
Delete EVERGREEN ENERGY INC EEE United States Energy
Add EVOLUTION PETROLEUM CORP EPM United States Energy
Add EXACT SCIENCES CORP EXAS United States Health Care
Add EXCEL MARITIME CARRIERS EXM United States Producer Durables
Add EXCEL TR INC EXL United States Financial Services
Add EXPRESS INC EXPR United States Consumer Discretionary
Delete FARMERS CAPITAL BK CORP FFKT United States Financial Services
Add FEDERAL AGRIC MTG CO AGM United States Financial Services
Add FEDERAL HOME LN MTG CORP FRE United States Financial Services
Add FIBERTOWER CORP FTWR United States Utilities
Add FINANCIAL ENGINES INC FNGN United States Financial Services
Add FINISAR CORP FNSR United States Technology
Delete FIRST ACCEPTANCE CORP FAC United States Financial Services
Delete FIRST CALIFORNIA FINL GR FCAL United States Financial Services
Delete FIRST DEFIANCE FINANCIAL FDEF United States Financial Services
Delete FIRST FINL NORTHWEST FFNW United States Financial Services
Delete FIRST FINL SVC CORP FFKY United States Financial Services
Add FIRST INTST BANCSYSTEM FIBK United States Financial Services
Add FIVE STAR QUALITY CARE FVE United States Health Care
Delete FRISCHS RESTAURANTS INC FRS United States Consumer Discretionary
Add FSI INTL INC FSII United States Technology
Delete FUQI INTERNATIONAL INC FUQI United States Consumer Discretionary
Delete FUSHI COPPERWELD INC FSIN United States Materials & Processing
Add GASTAR EXPL LTD GST United States Energy
Add GENERAL GROWTH PPTYS INC GGP United States Financial Services
Delete GENERAL STEEL HOLDINGS GSI United States Materials & Processing
Delete GEOKINETICS INC GOK United States Energy
Add GEORGIA GULF CORP GGC United States Materials & Processing
Add GERBER SCIENTIFIC INC GRB United States Producer Durables
Add GERDAU AMERISTEEL CORP GNA United States Materials & Processing
Add GEROVA FINANCIAL GROUP GFC United States Financial Services
Add GLOBAL GEOPHYSICAL SVCS GGS United States Energy
Add GLOBALSTAR INC GSAT United States Utilities
Add GLOBE SPECIALTY METALS GSM United States Materials & Processing
Add GOLDEN STAR RES LTD CDA GSS United States Materials & Processing
Add GOLUB CAP BDC INC GBDC United States Financial Services
Delete GRAMERCY CAPITAL CORP GKK United States Financial Services
Delete GRAN TIERRA ENERGY INC GTE United States Energy
Add GRAY TELEVISION INC GTN United States Consumer Discretionary
Delete GREAT WOLF RESORTS INC WOLF United States Consumer Discretionary
Add GREEN BANKSHARES INC GRNB United States Financial Services
Delete GSE SYS INC GVP United States Technology
Delete GTX INC GTXI United States Health Care
Delete GUARANTY BANCORP GBNK United States Financial Services
Add GUIDANCE SOFTWARE INC GUID United States Technology
Add HALLADOR ENERGY CO HNRG United States Energy
Delete HAMPTON ROADS BANKSHARES HMPR United States Financial Services
Add HANMI FINANCIAL CORP HAFC United States Financial Services
Delete HARBIN ELECTRIC INC HRBN United States Producer Durables
Delete HARVARD BIOSCIENCE INC HBIO United States Health Care
Add HEALTHTRONICS INC HTRN United States Health Care
Delete HEMISPHERX BIOPHARMA INC HEB United States Health Care
Delete HERITAGE CRYL CLEAN INC HCCI United States Producer Durables
Add HFF INC HF United States Financial Services
Delete HICKORY TECH CORP HTCO United States Utilities
Add HOKU CORPORATION HOKU United States Energy
Add HOUSTON AMERICAN ENERGY HUSA United States Energy
Delete HQ SUSTAINABLE MARITIM HQS United States Consumer Staples
Add HUDSON HIGHLAND GROUP HHGP United States Producer Durables
Add HUDSON VALLEY HOLDING HUVL United States Financial Services
Delete HURCO COMPANIES INC HURC United States Producer Durables
Add HUTCHINSON TECHNOLOGY HTCH United States Technology
Add HYPERCOM CORP HYC United States Technology
Add ICO GLOBAL COMM HLDGS ICOG United States Utilities
Delete IDERA PHARMACEUTICALS IDRA United States Health Care
Add IDT CORP IDT United States Utilities
Add IKANOS COMMUNICATIONS IKAN United States Technology
Delete IMERGENT INC IIG United States Technology
Delete INCONTACT INC SAAS United States Utilities
Delete INDEPENDENCE HOLDING CO IHC United States Financial Services
Delete INFORMATION SERVICES GRP III United States Financial Services
Add INGERSOLL-RAND PLC IR United States Producer Durables
Add INHIBITEX INC INHX United States Health Care
Delete INNODATA ISOGEN INC INOD United States Producer Durables
Delete INNOSPEC INC IOSP United States Materials & Processing
Add INOVIO PHARMACEUTICALS INO United States Health Care
Delete INSMED INC INSM United States Health Care
Delete INTEGRATED ELECTRICAL SV IESC United States Producer Durables
Add INTEGRATED SILICON S ISSI United States Technology
Delete IPASS INC IPAS United States Consumer Discretionary
Add IRIDIUM COMMUNICATIONS IRDM United States Utilities
Delete ISTA PHARMACEUTICALS INC ISTA United States Health Care
Delete JACKSON HEWITT TAX SVC JTX United States Consumer Discretionary
Add JAGUAR MNG INC JAG United States Materials & Processing
Add JAMBA INC JMBA United States Consumer Discretionary
Delete JAVELIN PHARMACEUTICALS JAV United States Health Care
Add JAZZ PHARMACEUTICALS INC JAZZ United States Health Care
Add JOES JEANS INC JOEZ United States Consumer Discretionary
Add JOHNSON OUTDOORS INC JOUT United States Consumer Discretionary
Delete K V PHARMACEUTICAL CO KV.A United States Health Care
Add KEITHLEY INSTRS INC KEI United States Producer Durables
Add KENNEDY-WILSON HLDGS INC KW United States Financial Services
Delete KENTUCKY FIRST FEDERAL KFFB United States Financial Services
Add KERYX BIOPHARMACEUTICALS KERX United States Health Care
Add KID BRANDS INC KID United States Consumer Discretionary
Add KIT DIGITAL INC KITD United States Technology
Add KMG CHEMICALS INC KMGB United States Materials & Processing
Add KODIAK OIL & GAS CORP KOG United States Energy
Delete KOHLBERG CAPITAL CORP KCAP United States Financial Services
Add KRATOS DEFENSE & SEC SOL KTOS United States Producer Durables
Add L & L ENERGY INC LLEN United States Energy
Add LACROSSE FOOTWEAR INC BOOT United States Consumer Discretionary
Add LADENBURG THALMAN FIN LTS United States Financial Services
Delete LAKES ENTERTAINMENT INC LACO United States Consumer Discretionary
Add LEAR CORP LEA United States Consumer Discretionary
Add LECG CORP XPRT United States Producer Durables
Add LEE ENTERPRISES INC LEE United States Consumer Discretionary
Delete LEGACY BANCORP INC LEGC United States Financial Services
Add LIBBEY INC LBY United States Consumer Discretionary
Add LIFETIME BRANDS INC LCUT United States Consumer Discretionary
Delete LIHUA INTERNATIONAL INC LIWA United States Producer Durables
Add LIMONEIRA CO LMNR United States Consumer Staples
Add LIONS GATE ENTMNT CORP LGF United States Consumer Discretionary
Add LOCAL COM CORP LOCM United States Technology
Add LTX-CREDENCE CORP LTXC United States Technology
Delete LUBYS INC LUB United States Consumer Discretionary
Delete LULULEMON ATHLETICA INC LULU United States Consumer Discretionary
Add LYDALL INC LDL United States Producer Durables
Add MAGMA DESIGN AUTOMATION LAVA United States Technology
Add MAGNUM HUNTER RES CORP MHR United States Energy
Delete MANNATECH INC MTEX United States Consumer Staples
Add MARINEMAX INC HZO United States Consumer Discretionary
Add MARLIN BUSINESS SVCS MRLN United States Producer Durables
Delete MATRIXX INITIATIVES INC MTXX United States Health Care
Add MATTSON TECHNOLOGY INC MTSN United States Technology
Add MAXLINEAR INC MXL United States Technology
Add MCCLATCHY CO MNI United States Consumer Discretionary
Add MEDIA GENERAL INC MEG United States Consumer Discretionary
Delete MEMSIC INC MEMS United States Technology
Delete MERCADOLIBRE INC MELI United States Consumer Discretionary
Delete MERCER INS GROUP INC MIGP United States Financial Services
Add MERU NETWORKS INC MERU United States Technology
Add METALS USA HLDGS CORP MUSA United States Materials & Processing
Add MGP INGREDIENTS INC MGPI United States Consumer Staples
Add MIDWESTONE FINL GROUP MOFG United States Financial Services
Add MILLER PETE INC MILL United States Energy
Add MINDSPEED TECHNOLOGIES MSPD United States Technology
Delete MOLECULAR INSIGHT PHARMA MIPI United States Health Care
Add MOSYS INC MOSY United States Technology
Add MPG OFFICE TRUST INC MPG United States Financial Services
Delete MYRIAD PHARMA INC MYRX United States Health Care
Add NANOMETRICS INC NANO United States Technology
Add NATIONAL AMERN UNIV NAUH United States Consumer Discretionary
Add NATURES SUNSHINE PRODS NATR United States Consumer Staples
Add NEOSTEM INC NBS United States Health Care
Delete NESS TECHNOLOGIES INC NSTC United States Technology
Delete NET 1 UEPS TECHNOLOGIES UEPS United States Financial Services
Add NETWORK ENGINES INC NENG United States Technology
Add NEURALSTEM INC CUR United States Health Care
Add NEWCASTLE INVT CORP NCT United States Financial Services
Add NEXSTAR BROADCASTING GRP NXST United States Consumer Discretionary
Delete NIGHTHAWK RADIOLOGY HLDG NHWK United States Health Care
Delete NIVS INTELLIMEDIA TECH NIV United States Consumer Discretionary
Delete NOBEL LEARNING CMNTYS NLCI United States Consumer Discretionary
Add NORANDA ALUM HLDG CORP NOR United States Materials & Processing
Delete NORTHEAST CMNTY BANCORP NECB United States Financial Services
Delete NORTHRIM BANCORP INC NRIM United States Financial Services
Delete NORWOOD FINANCIAL CORP NWFL United States Financial Services
Delete NOVAMED INC NOVAD United States Health Care
Add OCCAM NETWORKS INC OCNW United States Technology
Add OCLARO INC OCLR United States Technology
Delete ODYSSEY MARINE EXPLOR OMEX United States Producer Durables
Delete OHIO VY BANC CORP OVBC United States Financial Services
Delete OILSANDS QUEST INC BQI United States Energy
Delete OLD POINT FINL CORP OPOF United States Financial Services
Delete OLD SECOND BANCORP INC OSBC United States Financial Services
Delete OMEGA PROTEIN CORP OME United States Consumer Staples
Delete ONCOGENEX PHARMAS INC OGXI United States Health Care
Add ONE LIBERTY PROPERTIES OLP United States Financial Services
Delete ORCHIDS PAPER PRODS COMP TIS United States Consumer Staples
Delete ORION ENERGY SYSTEMS INC OESX United States Materials & Processing
Delete OVERHILL FARMS INC OFI United States Consumer Staples
Delete OXIGENE INC OXGN United States Health Care
Add P A M TRANSN SVCS INC PTSI United States Producer Durables
Delete PACIFIC CAPITAL BANCORP PCBC United States Financial Services
Delete PAR TECHNOLOGY CORP PTC United States Technology
Delete PARAMOUNT GOLD & SILVER PZG United States Materials & Processing
Add PARK OHIO HOLDINGS CORP PKOH United States Producer Durables
Delete PARKERVISION INC PRKR United States Technology
Delete PC MALL INC MALL United States Technology
Add PDF SOLUTIONS INC PDFS United States Technology
Add PDI INC PDII United States Producer Durables
Delete PENNICHUCK CORP PNNW United States Utilities
Delete PEOPLES FINL CORP MISS PFBX United States Financial Services
Add PEREGRINE PHARMA INC PPHM United States Health Care
Delete PERMA-FIX ENVIRONMENTAL PESI United States Producer Durables
Delete PERVASIVE SOFTWARE INC PVSW United States Technology
Add PGT INC PGTI United States Materials & Processing
Add PHARMACYCLICS INC PCYC United States Health Care
Delete PHOENIX TECHNOLOGIES LTD PTEC United States Technology
Add PILGRIMS PRIDE CORP NEW PPC United States Consumer Staples
Add PINNACLE AIRL CORP PNCL United States Producer Durables
Delete PONIARD PHARMA INC PARD United States Health Care
Delete PORTEC RAIL PRODUCTS INC PRPX United States Producer Durables
Delete PREMIERWEST BANCORP PRWT United States Financial Services
Add PRESSTEK INC PRST United States Producer Durables
Delete PRIMEENERGY CORP PNRG United States Energy
Add PRIMERICA INC PRI United States Financial Services
Add PROSPECT MEDICAL HLDGS PZZ United States Health Care
Delete PROTALIX BIOTHERAPEUTICS PLX United States Health Care
Delete PRUDENTIAL BANCORP INC PBIP United States Financial Services
Add PURE BIOSCIENCE PURE United States Health Care
Delete QC HOLDINGS INC QCCO United States Financial Services
Add QUALITY DISTRIBUTION INC QLTY United States Producer Durables
Add RADIO ONE INC ROIAK United States Consumer Discretionary
Delete RADNET INC RDNT United States Health Care
Delete RAE SYSTEMS INC RAE United States Producer Durables
Add RAM ENERGY RESOURCES INC RAME United States Energy
Delete RASER TECHNOLOGIES INC RZ United States Energy
Add REACHLOCAL INC RLOC United States Consumer Discretionary
Delete READING INTERNATIONAL RDI United States Consumer Discretionary
Add RENTECH INC RTK United States Materials & Processing
Delete REPLIGEN CORP RGEN United States Health Care
Delete REPROS THERAPEUTICS INC RPRX United States Health Care
Delete REPUBLIC FIRST BANCORP FRBK United States Financial Services
Add RESOLUTE ENERGY CORP REN United States Energy
Delete RESOURCE AMERICA INC REXI United States Financial Services
Add RETAIL OPPORTUNITY INVTS ROIC United States Financial Services
Delete REWARDS NETWORK INC DINE United States Financial Services
Add RICHARDSON ELECTRONICS RELL United States Technology
Add ROADRUNNER TRNSN SVCS RRTS United States Producer Durables
Delete ROCKWELL MEDICAL TECH RMTI United States Health Care
Add RODMAN & RENSHAW CAP GP RODM United States Financial Services
Add RURAL/METRO CORP RURL United States Health Care
Add SANFILIPPO JOHN B & SON JBSS United States Consumer Staples
Add SANMINA SCI CORP SANM United States Technology
Add SCORPIO TANKERS INC STNG United States Producer Durables
Add SELECT COMFORT CORP SCSS United States Consumer Discretionary
Add SENOMYX INC SNMX United States Materials & Processing
Add SENORX INC SENO United States Health Care
Delete SHENGDA TECH INC SDTH United States Materials & Processing
Add SHILOH INDUSTRIES INC SHLO United States Materials & Processing
Delete SHORE BANCSHARES INC SHBI United States Financial Services
Add SIRIUS XM RADIO INC SIRI United States Consumer Discretionary
Delete SMARTHEAT INC HEAT United States Producer Durables
Delete SMITHTOWN BANCORP INC SMTB United States Financial Services
Delete SOHU COM INC SOHU United States Technology
Add SOLTA MEDICAL INC SLTM United States Health Care
Add SOMAXON PHARMACEUTICALS SOMX United States Health Care
Add SONIC SOLUTIONS SNIC United States Technology
Delete SOUTH FINANCIAL GROUP TSFG United States Financial Services
Add SPANSION INC CODE United States Technology
Add SPECTRUM BRANDS INC SPB United States Consumer Staples
Add SPS COMM INC SPSC United States Technology
Add SS&C TECHNOLOGIES HLDGS SSNC United States Technology
Add STAAR SURGICAL CO STAA United States Health Care
Delete STANLEY FURNITURE CO INC STLY United States Consumer Discretionary
Delete STARTEK INC SRT United States Producer Durables
Delete STERLING FINL CORP WA STSA United States Financial Services
Add STREAM GLOBAL SVCS INC SGS United States Producer Durables
Delete SULPHCO INC SUF United States Energy
Add SUMMER INFANT INC SUMR United States Consumer Discretionary
Delete SUN BANCORP INC NJ SNBC United States Financial Services
Add SUPERMEDIA INC SPMD United States Consumer Discretionary
Delete SUREWEST COMMUNICATIONS SURW United States Utilities
Delete SUTOR TECH GROUP LTD SUTR United States Materials & Processing
Add SXC HEALTH SOLUTIONS SXCI United States Health Care
Delete SYMS CORP SYMS United States Consumer Discretionary
Add SYNERON MEDICAL LTD ELOS United States Health Care
Add TARGACEPT INC TRGT United States Health Care
Add TAYLOR CAPITAL GROUP INC TAYC United States Financial Services
Add TELENAV INC TNAV United States Technology
Add TESCO CORP TESO United States Energy
Add TESSCO TECHNOLOGIES INC TESS United States Technology
Delete TGC INDUSTRIES INC TGE United States Energy
Add THERMADYNE HLDGS CORP THMD United States Producer Durables
Add THL CR INC TCRD United States Financial Services
Add THOMAS PROPERTIES GROUP TPGI United States Financial Services
Add THOMPSON CREEK METALS TC United States Materials & Processing
Add THOMSON REUTERS CORP TRI United States Financial Services
Delete TODD SHIPYARDS CORP TOD United States Producer Durables
Delete TOREADOR RESOURCES CORP TRGL United States Energy
Delete TOWN SPORTS INTL CLUB United States Consumer Discretionary
Add TPC GROUP INC TPCG United States Materials & Processing
Delete TRANS1 INC TSON United States Health Care
Add TRANSATLANTIC PETROLEUM TAT United States Energy
Add TRANSCEPT PHARM INC TSPT United States Health Care
Delete TRANSCONTINENTAL REALTY TCI United States Financial Services
Delete TREE.COM INC TREE United States Financial Services
Add TWO HBRS INVT CORP TWO United States Financial Services
Add TYCO INTERNATIONAL LTD TYC United States Producer Durables
Add U S ENERGY CORP USEG United States Materials & Processing
Delete U S GEOTHERMAL INC HTM United States Energy
Delete U S GLOBAL INVS INC GROW United States Financial Services
Add ULTRA CLEAN HOLDINGS INC UCTT United States Technology
Add ULTRA PETROLEUM CORP UPL United States Energy
Delete ULTRALIFE CORPORATION ULBI United States Producer Durables
Add UNILIFE CORP NEW UNIS United States Health Care
Delete UNITED SECURITY BANC INC USBI United States Financial Services
Delete UNIVERSAL TRAVEL GROUP UTA United States Consumer Discretionary
Add UQM TECHNOLOGIES INC UQM United States Producer Durables
Delete URANERZ ENERGY CORP URZ United States Materials & Processing
Delete UTAH MED PRODS INC UTMD United States Health Care
Delete VALENCE TECHNOLOGY INC VLNC United States Producer Durables
Delete VALHI INC VHI United States Materials & Processing
Add VERSO PAPER CORP VRS United States Materials & Processing
Add VIASYSTEMS GROUP INC VIAS United States Technology
Add VIRGINIA COMM BANCORP VCBI United States Financial Services
Add VIRNETX HOLDING CORP VHC United States Technology
Add VISTAPRINT N V VPRT United States Consumer Discretionary
Add VONAGE HLDGS CORP VG United States Utilities
Add WABASH NATIONAL CORP WNC United States Producer Durables
Add WARNER CHILCOTT PLC WCRX United States Health Care
Add WAVE SYSTEMS CORP WAVX United States Technology
Add WEATHERFORD INTL WFT United States Energy
Delete WEB.COM GROUP INC WWWW United States Technology
Add WEST COAST BANCORP WCBO United States Financial Services
Delete WESTMORELAND COAL CO WLB United States Energy
Add WESTWOOD ONE INC WWON United States Consumer Discretionary
Delete WILBER CORP GIW United States Financial Services
Delete WILLIS LEASE FINANCE WLFC United States Producer Durables
Add WINMARK CORP WINA United States Consumer Discretionary
Delete WONDER AUTO TECH INC WATG United States Consumer Discretionary
Add XERIUM TECHNOLOGIES INC XRM United States Producer Durables
Add XYRATEX LTD XRTX United States Technology
Delete YADKIN VALLEY FINL CORP YAVY United States Financial Services
Delete YRC WORLDWIDE INC YRCW United States Producer Durables
Delete ZALE CORP ZLC United States Consumer Discretionary
Delete ZHONGPIN INC HOGS United States Consumer Staples
Delete ZION OIL & GAS INC ZN United States Energy
Add ZIOPHARM ONCOLOGY INC ZIOP United States Health Care
Russell posts lists of index additions
Annual process ensures each index reflects true market segments
http://www.russell.com/News/Press_Releases/PR20100611.asp
Tacoma, WA — June 11, 2010 — Russell Investments has posted its official lists of companies that are set to join or leave the broad-market Russell 3000® Index when its industry-leading U.S. equity indexes are reconstituted on June 25. These lists of U.S. companies—and lists of additions and deletions for the Russell Global Index—are available at www.russell.com/Indexes/membership/Reconstitution/default.asp.
With these changes the combined market capitalization of stocks in the Russell 3000, which reflects about 98% of the investable U.S. equity universe, will increase from $10.6 trillion at this point last year to $13.4 trillion. Similarly, the median market capitalization will increase by 38.8% from $578 million at this point last year to $802 million.
Exxon Mobil will continue to rank as the largest company in the index in terms of market capitalization, despite a 16.3% decline since last year's index reconstitution, and Berkshire Hathaway will move into the top 10, clearly making it the largest stock set for addition to the index this year.
Today's list of preliminary additions for the Russell 3000 features 262 companies, including 47 firms in the technology sector, 46 in the health care sector and 41 in the consumer discretionary sector.
"Reconstitution is a key feature of truly representative benchmarks," said Rolf Agather, head of index research and innovation at Russell. "Russell's unique process completely recalibrates Russell's U.S. Indexes to today's market realities, ensuring that stocks are moved into the right 'buckets' to truly represent small-cap, midcap, large-cap and microcap stocks. It also serves as a clear measure of the shifts in relative valuations of value and growth stocks over the past year."
Today's preliminary lists of additions and deletions represent the first public step in Russell's annual reconstitution process. Any updates to these lists will be posted June 18 and 25. The final membership lists for the Russell 3000, Russell 2000® Index and Russell 1000® Index will be posted June 28.
Membership in Russell's U.S. equity Indexes—widely used as benchmarks for both passive and active investment strategies—is determined by objective rules, such as market capitalization rankings. Accurate benchmarks are an integral part of Russell's ongoing process to monitor more than 8,000 investment manager products worldwide for Russell's $179 billion active investment management business.
Contacts:
Steve Claiborne, 253-439-1858
Keryx (KERX) Conference Call Rundown
June 10th, 2010
http://www.gekkowire.com/?p=3784
So I took some time to listen to the two Keryx Investors Presentations held yesterday and today. I’ll give investors a brief rundown on the important information. Since most investors in the company are aware that they have 2 drugs in 3 Phase III SPA trials, I will stay away from drug data as I have already covered Perifosine in depth during this year’s ASCO.
The most important information that I took away from the conference calls was that the company seems to be more than willing to partner up to develop and commercialize the drug. The company was noted as saying that there was a “robust” interest in the two compounds Perifosine and Zerenex. I’m going to add in my two cents here, if the company is unable to find a partner until they finish Phase III trials, then I would much rather have them commercialize the drugs themselves. The big risk is in getting the drug through the Phase III trials.
The FDA is not so much of a risk if your data is strong, compelling, and establishes safety and efficacy. I have seen several companies partner up after passing Phase III trials (Protalix is one htat comes to mind), only to watch shareholders get jimmied out of the massive returns like Dendreon has shown. A little dilution hurts a lot less than having all your revenues taken away so you can receive a measley royalty rate and milestone payment. So my take on this is the following: if Keryx cannot partner up during the Phase III trials, and the drug passes the trial, then I would want them to go at it alone. the company also noted that they should be seeing some data from the colorectal trial sometime in the 2nd half of 2011.
Keryx also reiterated that they have plenty of cash to run the clinical trials. The company said that they were sitting on about $32 million at the current moment and are burning about $1.5 million per month and expect to burn about $18 million this year. They also noted that they should receive a milestone payment and an options exercise somewhere in the amount of $15-17 million later this year which would leave them with about $47 million in cash.
YRC Worldwide Expects Positive Results In Q2, Plans Reverse Stock Split - Update
5/25/2010 3:01 PM ET
http://www.rttnews.com/ArticleView.aspx?Id=1315821
...Further, the company said it expects a reverse stock split within the next few months with the split ratio ranging from 1:25 to 1:5.
AEterna Zentaris (AEZS) and Keryx Biopharmaceuticals Share Price Parity
May 28th, 2010
http://www.gekkowire.com/?p=3670
ZOOM Technologies: China Watch
Fri 06/11/10 12:00 PM EST -- Brittany Umar
http://www.thestreet.com/_yahoo/video/10780581/zoom-technologies-china-watch.html?cm_ven=YAHOOV&cm_cat=FREE&cm_ite=NA&s=1#91280565001
NEW YORK--Anthony Chan, CFO of ZOOM Technologies, details his company's presence within China's mobile market, how the company stands to be impacted by the arrival of Apple's iPhone and iPad in China and how he anticipates his company's growth as the China mobile market becomes more penetrated.
ZOOM Technologies: China Watch
Fri 06/11/10 12:00 PM EST -- Brittany Umar
http://www.thestreet.com/_yahoo/video/10780581/zoom-technologies-china-watch.html?cm_ven=YAHOOV&cm_cat=FREE&cm_ite=NA&s=1#91280565001
NEW YORK--Anthony Chan, CFO of ZOOM Technologies, details his company's presence within China's mobile market, how the company stands to be impacted by the arrival of Apple's iPhone and iPad in China and how he anticipates his company's growth as the China mobile market becomes more penetrated.
Unilife Appoints Richard Wieland as Executive Vice President and Chief Financial Officer
Date : 06/10/2010 @ 5:11PM
Source : PR Newswire
Stock : Unilife (MM) (UNIS)
http://ih.advfn.com/p.php?pid=nmona&article=43187310&symbol=UNIS
Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that it has appointed R. Richard Wieland II as its Executive Vice President and Chief Financial Officer (CFO). Mr. Wieland will oversee the management of Unilife's finance and accounting, human resources and IT operations. He will be immediately replacing Unilife's current CFO Dan Calvert, who is relocating to his home state of Indiana for family reasons.
Mr. Wieland, 65, has over 30 years of senior financial experience with U.S.-based public and private companies. He has served as the CFO of four NASDAQ-listed companies within the life sciences industry, and as a senior executive of two New York Stock Exchange-listed companies.
Most recently, Mr. Wieland served as the CFO of Cytochroma Inc., a privately-held specialty pharmaceutical company. From 2004 to 2008, Mr. Wieland served as Executive Vice-President and CFO of Advanced Life Sciences Holdings, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company. Prior to that, Mr. Wieland served as a senior executive of other NASDAQ-listed life science and healthcare companies, including Option Care, Inc., where he was a Board member, President and Chief Operating Offer.
Mr. Wieland received his MBA from Washington University in St. Louis, MO, and his BA in Accounting and Economics from Monmouth College in Monmouth, IL, where he later served as a member of the Board of Trustees. Mr. Wieland is a past member of the National Investor Relations Institute, Financial Executives International and the U.S. Army Signal Corps.
Mr. Alan Shortall, Chief Executive Officer of Unilife, said, "Richard has an outstanding record and we are extremely pleased to add him to the Unilife team. The appointment of such experienced and well-respected financial executives in the healthcare and pharmaceutical markets as Richard and our new Board member Mary Kate Wold reflects our continuing efforts to improve our already outstanding team, and will support our growth as a U.S. based emerging global leader for innovative medical devices.
"Richard has extensive knowledge and broad expertise in U.S. financial markets with a special emphasis in the production of products consumed within global healthcare and pharmaceutical industries. We are confident that Richard possesses the skills required to support Unilife during this period of rapid growth as we transition into a preferred supplier of devices for pharmaceutical and healthcare companies. It is important that Unilife continues to attract highly qualified individuals that share our strategic vision and possess the necessary expertise to contribute towards the continued delivery of our goals and business milestones."
Continued Shortall, "I would also like to extend our gratitude to Dan Calvert for his commitment to Unilife over the past two years. We wish him the very best in all his future endeavors."
Mr. Wieland stated, "With Unilife's unique and revolutionary technology, I anticipate that the Company will quickly become a strong international leader in the fast-growing pharmaceutical market for prefilled syringes. I am excited to begin working with Alan and the Unilife team, incorporating my skills and experiences to ensure that we capitalize on our leading technologies and established partnerships with leading healthcare and pharmaceutical companies. My primary responsibility will be to ensure that financial accountability continues to be rigorously applied as we roll out and expand our product portfolio."
About Unilife Corporation
Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.
General: UNIS-G
Investor Contacts (US):
Investor Contacts (Australia)
Todd Fromer / Garth Russell
Stuart Fine
Jeff Carter
KCSA Strategic Communications
Carpe DM Inc
Unilife Corporation
Phone + 1 212-682-6300
Phone + 1 908 469 1788
Phone + 61 2 8346 6500
SOURCE Unilife Corporation
CytoSorbents Corporation to Present at the In3 East Medical Device Conference
Date : 06/08/2010 @ 7:30AM
Source : MarketWire
Stock : CytoSorbents Corporation (CTSO)
http://ih.advfn.com/p.php?pid=nmona&article=43136544&symbol=NB^CTSO
CytoSorbents Corporation (OTCBB: CTSO) announced that its Chief Executive Officer and President, Dr. Phillip Chan, will deliver a presentation at the In3 East Medical Device Conference at the Westin Copley Place Hotel in Boston, MA on Thursday, June 10, 2010 at 3:20PM EDT. www.in3east.com
"As we work towards CE Mark approval of our flagship product CytoSorb?, we are pleased to discuss the numerous potential clinical applications of our technology with potential investors and strategic partners. CytoSorb? was uniquely designed to reduce cytokine storm, or the excessive overproduction of cytokines, responsible for the severe inflammation, organ failure and patient death seen in many critical care diseases. Most of these diseases, such as severe sepsis and septic shock, burn and smoke inhalation injury, acute respiratory distress syndrome, acute severe pancreatitis, advanced influenza, trauma and others have limited treatment options and are typically treated with only supportive care therapies and watchful waiting today. CytoSorb represents a new generation of 'active' therapies that can potentially reverse or eliminate the underlying damaging cytokine storm, allowing patients to heal and recover faster and to get out of the hospital alive more quickly. We believe the future treatment of critical care diseases revolves around this important concept."
About CytoSorbents and CytoSorb?
CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a therapeutic device company in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood purification device called CytoSorb?. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body's abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called "cytokine storm," that then causes multi-organ failure and often death. CytoSorb? is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb? cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using CytoSorb? to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb? in the European Union. CytoSorb? is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, burn and smoke inhalation injury and rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company's website: www.cytosorbents.com
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.
Contact:
CytoSorbents Corporation
David Lamadrid
(732) 329-8885 ext. 816
davidl@cytosorbents.com
Cardium Announces Master Services Agreement With bioRASI for Planned Late-Stage Clinical Study and Commercialization Activities for Generx Product Candidate in International Markets
http://www.finanznachrichten.de/nachrichten-2010-06/17122717-cardium-announces-master-services-agreement-with-biorasi-for-planned-late-stage-clinical-study-and-commercialization-activities-for-generx-product-can-008.htm
SAN DIEGO, June 10 /PRNewswire-FirstCall/ --
Cardium Therapeutics (NYSE Amex: CXM) today announced that it has entered into a Master Services Agreement with bioRASI, an international contract research organization, to assist Cardium in the conduct of a planned late-stage clinical study and commercialization activities for Cardium's Generx (Ad5FGF-4) drug candidate in Russia and affiliated jurisdictions, as well as in potentially other newly industrializing markets. Under the terms of the agreement, bioRASI will assist Cardium to conduct a late-stage clinical study to evaluate the efficacy and safety of Cardium's Generx product candidate at up to three leading medical centers in Moscow and to assist the Company in commercialization activities in these international markets.
(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)
The Generx clinical study is expected to be initiated in the second half of this year and will be a randomized, controlled, parallel-group, multicenter study to evaluate the safety and efficacy of Generx using adenosine SPECT imaging of myocardial blood flow in patients with stable angina pectoris. The primary endpoint will be the change in reversible perfusion defect size as measured by adenosine SPECT imaging, which is directly analogous to that successfully used in a Phase 2a clinical study of Generx.
Positive results from the prior Phase 2a clinical study (Grines et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx improved myocardial blood flow in the ischemic region of the hearts of men and women following a single intracoronary infusion as measured by the objective efficacy endpoint of SPECT imaging. As noted in the publication, the mean change observed in Generx-treated patients was a 4.2% absolute reduction (which represents a 20% relative reduction) in the reversible perfusion defect size from baseline at eight weeks (p<0.001), while the placebo group showed only a 1.6% absolute reduction from baseline (not significant) at eight weeks following treatment. The observed treatment effect for patients receiving Generx was similar in magnitude to that reported in the literature for patients undergoing angioplasty/stent or revascularization procedures with reversible perfusion defects of comparable size at one year following these procedures.
The Company believes that Generx could potentially be developed as a cost effective front-line therapy for patients with coronary artery disease in the large markets of newly-industrializing countries who often do not have access to costly advanced care procedures such as coronary angioplasty and stenting, or cardiac bypass surgery (which in the U.S. can cost $50,000 to $100,000 over a five-year period following initial treatment). Having such additional clinical evidence confirming the safety and effectiveness of Generx for improving coronary collateral circulation in men and women with severe coronary artery disease could also potentially be used to optimize and broaden commercial development pathways in the U.S. and other major markets such as Europe.
"We are pleased to be working with bioRASI as their expansive global clinical research experience should provide Cardium with an effective and cost-efficient means of advancing our Generx product development efforts and expanding our clinical database to support the potential commercialization of this novel product candidate. Based on data indicating that Generx appears to safe and has the potential to substantially increase coronary blood flow in the context of heart disease, together with an independent 10-year study that underscored the significance of coronary circulation for long-term cardiac health, we believe that our Generx product candidate could be developed as a front-line therapy for coronary artery disease from a more global perspective. Additional data gained from our planned clinical study should also help support an expanded U.S. registration dossier by providing additional safety data and potentially alternative efficacy measures. The more objective SPECT imaging endpoint is designed to directly assess the ability of the heart to increase myocardial blood flow under conditions such as stress and is considered to be an important indicator of cardiac function and the ability of a patient's heart to effectively handle routine exercise and daily activities, which can have a dramatic impact on a patient's health and quality of life," stated Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer.
Generx Product Candidate
Generx (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic product candidate representing a new class of cardiovascular biologics as a treatment for patients with advanced coronary artery disease. Generx is designed to stimulate and promote the growth of supplemental collateral vessels to enhance myocardial blood flow (perfusion) following a one-time intracoronary administration from a standard cardiac infusion catheter in patients who have insufficient blood flow due to atherosclerotic plaque build-up in the coronary arteries. Generx has progressed through four randomized, placebo controlled clinical studies at over 100 medical centers in the United States and Western Europe that have enrolled over 650 patients.
About bioRASI
bioRASI is a full service global CRO that collaborates with the leading biotech and pharmaceutical companies in the clinical development of novel and generic therapeutics. bioRASI services include program management, regulatory, clinical, data management and analysis, compliance and audit. bioRASI leverages its access to world renowned researchers and facilities in the U.S., Europe and Asia, to achieve critical scientific, clinical and business results. bioRASI is headquartered in Hollywood, FL and has offices in Miami, Los Angeles, San Diego, Wilmington, NC and overseas in Moscow, Kiev, Belgrade, Riga and Mumbai. Information about bioRASI is available at http://www.biorasi.com/.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at http://www.cardiumthx.com/.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that Generx can be successfully advanced in clinical studies outside of the U.S.; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the regulatory or commercialization activities of Generx in the U.S. or other markets; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2010 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com/.
Cardium Therapeutics(TM) and Generx® and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM) and Osteorate(TM)
are trademarks of Tissue Repair Company.
Photo: AP Archive: http://photoarchive.ap.org/
http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO
PRN Photo Desk, photodesk@prnewswire.com
Cardium Therapeutics
CONTACT: Bonnie Ortega, Director, Investor/Public Relations of Cardium
Therapeutics, Inc., +1-858-436-1018, InvestorRelations@cardiumthx.com
Web Site: http://www.cardiumthx.com/
http://www.biorasi.com/
© 2010 PR Newswire
NexMed Provides Update on Canadian Filing for Vitaros®
Date : 06/10/2010 @ 1:30PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&article=43184243&symbol=NEXM
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission (“NDS”) with Health Canada for Vitaros®, the Company’s topical treatment for erectile dysfunction.
NexMed management has been advised that Health Canada is continuing to review its response for acceptance, and the Company expects to hear from the agency within the next 30 days. An acceptance of the response by Health Canada will trigger a new, 150-day review cycle by the NDS reviewers for a final approval or rejection of the marketing application.
On April 23, 2010, NexMed reported that it had received delivery confirmation of its response to the CMC (Chemistry, Manufacturing and Controls) concerns previously raised by Health Canada (the "Response") related to its New Drug Submission for Vitaros, which was filed in February 2008. The delivery confirmation provided Health Canada with a 45-day screening for acceptance process of the Response by their Regulatory Project Management group, or until approximately June 4, 2010.
Management of NexMed also stated today that the Company is not currently selling shares of its common stock pursuant to the agreement with Brinson Patrick Securities Corporation. Further information concerning the agreement with Brinson is available pursuant to the Company’s Form 10Q filed on May 13, 2010.
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that Health Canada will accept the Company’s response for review or approve Vitaros for sale in Canada.
4th Annual Jefferies Healthcare Conference (06/11/10)
Antisoma to present at 9th Annual Needham Life Sciences Conference and 4th Annual Jefferies Healthcare Conference in New York
Date : 06/04/2010 @ 7:00AM
http://ih.advfn.com/p.php?pid=nmona&article=43096649&symbol=L^ASM
04 June 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC:ATSMY) announces that Daniel Elger, VP Marketing & Communications, will present at the 4th Annual Jefferies Healthcare Conference in New York at 12.45 pm local time (5.45 pm BST) on Friday 11 June.
Enquiries:
Alison Saville
Senior Marketing and Communications Executive
Antisoma plc
+44 (0)20 3249 2100
Completion of Acquisition of Assets
Current report filing (8-K)
http://ih.advfn.com/p.php?pid=nmona&article=43126338&symbol=N^ZOOM
Date : 06/07/2010 @ 3:00PM
Source : Edgar (US Regulatory)
Stock : (ZOOM)
On June 1, 2010, Zoom Technologies, Inc. (the "Company") pursuant to a share exchange agreement (the "Agreement") dated April 29, 2010, acquired 100% of the shares of Nollec Wireless Company Ltd., ("Nollec Wireless") a mobile phone and wireless communication design company located in Beijing, China (the "Acquisition"). The parties to the Agreement include the Company as the acquirer of Nollec Wireless and:
a) Silver Tech Enterprises, Ltd. ("Silver Tech"), a holding company founded in July 2005, organized and existing under the laws of the British Virgin Islands, which owns 100% of Ever Elite Corporation, Ltd.;
b) Ever Elite Corporation, Ltd. ("Ever Elite"), a holding company founded in June 2007, organized under the laws of Hong Kong Special Administrative Region which owns 100% of Nollec Wireless Company, Ltd.;
c) Nollec Wireless Company, Ltd., the operating company founded in June 2007, organized under the laws of the People's Republic of China;
d) Key Network Holdings, Ltd. ("KNH"), a BVI company, owner of 76.8% of the outstanding stock of Silver Tech; and
e) Better Day Finance, Ltd. ("BDF"), a BVI company, owner of 23.2% of the outstanding stock of Silver Tech.
After the closing on June 1, 2010, each of Silver Tech, Ever Elite and Nollec Wireless became wholly owned subsidiaries of Zoom, as described in the diagram below:
KNH and BDF sold their combined 100% ownership of Silver Tech to the Company. The consideration paid for Silver Tech, which owns 100% of Ever Elite which in turn owns 100% of Nollec Wireless was US$10.96 million in cash and stock. The consideration paid by the Company is based on an appraisal report conducted by Beijing Jingdu Zhongxin Assets Valuation Company Ltd., an affiliate of Grant Thornton. Pursuant to the Agreement, $1.37 million of the total consideration was paid in cash by the Company and the balance of $9.59 million was paid by the issuance of 1,342,599 shares of the Company's common stock ("Payment Shares"). The price of the Payment Shares was based on the weighted average closing price of Zoom shares as traded on Nasdaq for the 10 consecutive trading days prior and leading up to the day immediately before the date of the Agreement. The sellers in the Transaction, KNH and BDF, executed lock up agreements which restrict them from transferring the Payment Shares for a period of 6 months from the closing date of the transaction. Closing of the Transaction was subject to customary closing conditions and deliverables by the Company, KNH and BDF.
Nollec Wireless primarily focuses on research and development of mobile phones, and hardware and software solutions for domestic Chinese and oversea customers. Its design team includes experienced engineers in the core technologies of wireless communication and mobile phone development. Nollec provides state of the art industrial, user inter-phase, mechanical and engineering designs and software and hardware integration. Its clients include certain domestic and international mobile phone manufacturers including Philips, Lenovo, Sonim, Gionee and Borqs.
Nollec Wireless generates revenues by charging clients a design fee plus a royalty fee based on the number of units of phones actually sold. Its unaudited financial results for the years ended December 31, 2009 and 2008 showed revenues of $6.2 million and $7.1 million respectively, and net income of $1.3 million and $0.9 million respectively.
Required Audited financial statements will be filed in an amendment on Form 8-K not later than 71 calendar days after the filing date of this report.
IBOX updated!
add <PersonMark> 2u
ax
Sunesis to Present at Upcoming Investor Conferences
Date : 06/03/2010 @ 7:30AM
Source : MarketWire
Stock : Sunesis Pharmaceuticals, Inc. (SNSS)
http://ih.advfn.com/p.php?pid=nmona&article=43079095&symbol=N^SNSS
SOUTH SAN FRANCISCO, CA -- (Marketwire)
06/03/10
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at three upcoming conferences:
9th Annual Needham Healthcare Conference
Wednesday, June 9 at 10:40 a.m. EDT
New York Palace Hotel, New York City
Jefferies 2010 Global Life Sciences Conference
Thursday, June 10 at 8:00 a.m. EDT
Grand Hyatt, New York City
ThinkEquity Mid Year Check-Up on Healthcare
Wednesday, June 16 at 11:30 a.m. EDT
The Princeton Club, New York City
A live webcast of the Jefferies presentation on June 10th will be available on the Sunesis website at http://ir.sunesis.com. A replay of that webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks following the presentation.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
Andrea Rabney
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Statement of Changes in Beneficial Ownership (4) 06/08/10
http://ih.advfn.com/p.php?pid=nmona&article=43149812&symbol=N%5ESNSS
http://ih.advfn.com/p.php?pid=nmona&article=43149814&symbol=N%5ESNSS
http://ih.advfn.com/p.php?pid=nmona&article=43149816&symbol=N%5ESNSS
http://ih.advfn.com/p.php?pid=nmona&article=43149818&symbol=N%5ESNSS
http://ih.advfn.com/p.php?pid=nmona&article=43149819&symbol=N%5ESNSS
http://ih.advfn.com/p.php?pid=nmona&article=43149828&symbol=N%5ESNSS
Conversion or Exercise Price of Derivative Security :
Stock Option (Right to Buy) $.815
9th Annual Needham Life Sciences Conference (06/10/10)
Antisoma to present at 9th Annual Needham Life Sciences Conference and 4th Annual Jefferies Healthcare Conference in New York
Date : 06/04/2010 @ 7:00AM
http://ih.advfn.com/p.php?pid=nmona&article=43096649&symbol=L^ASM
04 June 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC:ATSMY) announces that Daniel Elger, VP Marketing & Communications, will present at the 9th Annual Needham Life Sciences Conference in New York at 09.20 am local time (2.20 pm BST) on Thursday 10 June
A webcast of the presentation at the Needham conference will be available on Antisoma's website at http://www.antisoma.com/asm/media/webcast/
For live viewing of the webcast, it is recommended that viewers log on 15 minutes early in order to register and download any necessary software.
Enquiries:
Alison Saville
Senior Marketing and Communications Executive
Antisoma plc
+44 (0)20 3249 2100
Discovery Labs Reports Preliminary Results From Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
Date : 06/09/2010 @ 7:30AM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=43156243&symbol=N^DSCO
WARRINGTON, Pa., June 9, 2010
GLOBE NEWSWIRE
Discovery Laboratories, Inc. (Nasdaq:DSCO), reports preliminary results from its Phase 2 clinical trial of Surfaxin® in children with Acute Respiratory Failure (ARF), a critical condition often caused in children by severe respiratory infections. The objective of the study was to evaluate the safety and tolerability of intratracheal administration of Surfaxin and to assess whether Surfaxin treatment could decrease the duration of mechanical ventilation in children with ARF.
The Phase 2 trial was a multicenter, randomized, masked, placebo-controlled estimation trial that enrolled 165 children under the age of two with ARF and compared Surfaxin treatment to standard of care alone, masked with sham air control. All children enrolled received standard of care and were randomized to receive either Surfaxin at 5.8 mL/kg of body weight or sham air. The trial enrolled patients at 24 sites located in the northern and southern hemispheres.
Key preliminary observations in this Phase 2 trial are:
* Relative to the control treatment group, Surfaxin treatment reduced time on mechanical ventilation by approximately 10%, although this observation was not statistically significantly different. Duration on mechanical ventilation was 3.8 days for the Surfaxin treatment group versus 4.1 days for the control treatment group, expressed as the geometric mean (primary analysis per protocol).
* Surfaxin treatment appeared generally safe and well tolerated in this trial. Statistically significant differences in the incidence of bradycardia and desaturation were observed in the Surfaxin treatment group during the dosing period versus the control treatment group. Generally, such peri-dosing events are transient and expected with intratracheal surfactant administration.
Comprehensive analysis of the data from this trial is ongoing. Further assessment of safety and tolerability, as well as in-depth analysis of additional efficacy endpoints and patient sub-populations, is expected to be completed in the third quarter of 2010. Following this analysis, Discovery Labs in collaboration with the ARF Steering Committee plans to present the comprehensive results at relevant medical congresses and submit these data for publication in a peer review journal.
Robert Segal, MD, Chief Medical Officer and Senior Vice President of Discovery Labs, commented, "Pediatric Acute Respiratory Failure represents a significant medical challenge and, unfortunately, there are no approved medical therapies that effectively treat this disorder today. Pulmonary surfactant is critical for normal respiration and may become impaired following patient exposure to a pathogen such as influenza or respiratory syncytial virus. The comprehensive data set from this Phase 2 trial is being further analyzed with the study Steering Committee as we evaluate next steps. These data are important as we are assessing, for the first time, the safety, tolerability and efficacy of intratracheally administered Surfaxin in the ARF patient population."
Surfaxin is an investigational drug candidate that has not been approved by the FDA or any other world health regulatory authority.
About Acute Respiratory Failure
ARF in young children occurs primarily after they have been exposed to serious respiratory infections, such as influenza (including the type A serotype referred to as H1N1) or respiratory syncytial virus (RSV), and leads to an impairment in lung function and the need for endotracheal intubation and mechanical ventilation (the current standard of care). Children with ARF usually suffer surfactant inactivation as part of the disease process. When there is insufficient functional surfactant in the lung, the alveoli (air sacs) collapse and are unable to support sufficient oxygenation. ARF affects approximately 15,000 children under two years of age in the United States with an estimated 30,000 - 40,000 children afflicted in developed countries each year, depending on severity of the viral season. Presently there are no approved drugs for the treatment of ARF.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are: risks relating to the rigorous regulatory requirements required for approval of any drug or drug-device combination products that Discovery Labs may develop, including that: (a) Discovery Labs and the U.S. Food and Drug Administration (FDA) or other regulatory authorities will not be able to agree on the matters raised during regulatory reviews, or Discovery Labs may be required to conduct significant additional activities to potentially gain approval of its product candidates, if ever, (b) the FDA or other regulatory authorities may not accept or may withhold or delay consideration of any of Discovery Labs' applications, or may not approve or may limit approval of Discovery Labs' products to particular indications or impose unanticipated label limitations, and (c) changes in the national or international political and regulatory environment may make it more difficult to gain FDA or other regulatory approval; risks relating to Discovery Labs' research and development activities, including (i) time-consuming and expensive pre-clinical studies, clinical trials and other efforts, which may be subject to potentially significant delays or regulatory holds, or fail, and (ii) the need for sophisticated and extensive analytical methodologies, including an acceptable biological activity test, if required, as well as other quality control release and stability tests to satisfy the requirements of the regulatory authorities; risks relating to Discovery Labs' ability to develop and manufacture drug products and capillary aerosolization systems for clinical studies, and, if approved, for commercialization of drug and combination drug-device products, including risks of technology transfers to contract manufacturers and problems or delays encountered by Discovery Labs, its contract manufacturers or suppliers in manufacturing drug products, drug substances and capillary aerosolization systems on a timely basis or in an amount sufficient to support Discovery Labs' development efforts and, if approved, commercialization; the risk that Discovery Labs may be unable to identify potential strategic partners or collaborators to develop and commercialize its products, if approved, in a timely manner, if at all; the risk that Discovery Labs will not be able in a changing financial market to raise additional capital or enter into strategic alliances or collaboration agreements, or that the ongoing credit crisis will adversely affect the ability of Discovery Labs to fund its activities, or that additional financings could result in substantial equity dilution; the risk that Discovery Labs will not be able to access credit from its committed equity financing facilities (CEFFs), or that the minimum share price at which Discovery Labs may access the CEFFs from time to time will prevent Discovery Labs from accessing the full dollar amount potentially available under the CEFFs; the risk that Discovery Labs or its strategic partners or collaborators will not be able to retain, or attract, qualified personnel; the risk that Discovery Labs will be unable to regain compliance with The Nasdaq Capital Market listing requirements prior to the expiration of the additional grace period currently in effect, which could cause the price of Discovery Labs' common stock to decline; the risk that recurring losses, negative cash flows and the inability to raise additional capital could threaten Discovery Labs' ability to continue as a going concern; the risks that Discovery Labs may be unable to maintain and protect the patents and licenses related to its products, or other companies may develop competing therapies and/or technologies, or health care reform may adversely affect Discovery Labs; risks of legal proceedings, including securities actions and product liability claims; risks relating to health care reform; and other risks and uncertainties described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
CONTACT: Discovery Laboratories, Inc.
John G. Cooper, EVP and Chief Financial Officer
215-488-9300
Discovery Labs Receives FDA Guidance Regarding Preclinical Program to Gain Surfaxin(R) Approval
Date : 06/08/2010 @ 4:10PM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=43147378&symbol=N^DSCO
WARRINGTON, Pa., June 8, 2010
GLOBE NEWSWIRE
Discovery Laboratories, Inc. (Nasdaq:DSCO) announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that is consistent with its ongoing, comprehensive preclinical program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The safety and efficacy of Surfaxin for neonatal RDS has been previously demonstrated in a Phase 3 clinical program. If approved, Surfaxin would be the first synthetic, peptide-containing surfactant for commercial use in neonatal medicine. Discovery Labs believes it remains on track to complete the preclinical program and submit its Complete Response to the FDA in the first quarter of 2011.
Discovery Labs is now conducting a series of prospectively-designed, side-by-side preclinical studies employing both the newly-optimized and revalidated fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) and the well-established preterm lamb model of RDS. Discovery Labs plans to complete the preclinical program and submit a Complete Response taking into account the recently-received FDA comments. Multiple Surfaxin batches will be employed in the side-by-side preclinical studies to assess the short-term physiologic response following Surfaxin administration (via measurement of respiratory compliance) in both the preterm lamb model and the optimized BAT.
The resulting data will be examined to evaluate the relative changes in biologic activity of Surfaxin at several different time points over intended shelf life to determine the degree of comparability between the optimized BAT and the preterm lamb model. The FDA has indicated that, to satisfactorily establish comparability between the optimized BAT and the preterm lamb model, these data must demonstrate the same relative changes in respiratory compliance between both models over time. These studies are intended to also satisfy the FDA regarding the ability of the BAT to adequately discriminate biologically active from inactive Surfaxin drug product and establish the Surfaxin drug product's final acceptance criteria (with respect to biologic activity as assessed by the BAT) for release and ongoing stability.
Dr. Russell Clayton, Vice President, Research and Development, Preclinical and Regulatory Affairs commented, "Discovery's plan for the potential approval of Surfaxin continues to benefit from the FDA's direction and their recent suggestions have been incorporated into our plan. Another positive aspect of the most recent communication is the FDA's indicated willingness to continue to interact on our approach to gain potential Surfaxin approval."
In May 2010, Discovery Labs completed a key component of the comprehensive preclinical program, the optimization and revalidation of the BAT, having met all pre-specified acceptance criteria. Prior to optimizing and revalidating the BAT, Discovery Labs had several interactions with the FDA and submitted a proposed revalidation protocol, which also included pre-specified acceptance criteria. Within the next few weeks, Discovery Labs anticipates submitting to the FDA data and analysis from the recently completed optimization and revalidation of the BAT. This information, together with results from the ongoing side-by-side preclinical studies, is expected to be used by the FDA in its review of the planned Complete Response and its ultimate determination on whether to grant marketing approval for Surfaxin.
Discovery Labs believes that it is advantageously positioned to successfully complete the comprehensive preclinical program taking into consideration (i) the revalidation of its optimized BAT (meeting all pre-specified acceptance criteria), (ii) Discovery Labs' experience and relationships with well-recognized academic centers of excellence who routinely measure respiratory compliance in both the BAT and preterm lamb model, and (iii) the FDA's willingness to date to provide continued guidance regarding the Company's plans to resolve the remaining CMC matter.
Surfaxin is an investigational drug candidate that has not been approved by the FDA or any other world health regulatory authority.
DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking" statements relating, among other things, to Discovery Labs' understanding of the remaining questions identified in the April 2009 Complete Response Letter that must be addressed to gain FDA approval of Surfaxin and the outcomes of the June 2, 2009 end-of-review meeting, the September 29, 2009 teleconference held with the FDA, and the recently-received written guidance from the FDA. Although Discovery Labs currently believes that it is on track to submit the Complete Response in the first quarter of 2011 and may still succeed in gaining approval of its NDA for Surfaxin for the prevention of RDS in premature infants, these activities and the ultimate outcomes remain subject to a variety of risks and uncertainties that could cause actual results to be materially different. These risks and uncertainties include, but are not limited to, risks that (i) the FDA may not approve Surfaxin or may subject the marketing of Surfaxin to onerous requirements that significantly impair marketing activities; and (ii) Discovery Labs may identify unforeseen problems that have not yet been discovered or the FDA could in the future impose additional requirements to gain approval of Surfaxin. Any failure to satisfy the issues raised by the FDA, in the Complete Response letter or in related discussions, could significantly delay, or preclude outright, gaining approval of Surfaxin, which could potentially delay or prevent the approval of Discovery Labs' other products.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties are: risks relating to the rigorous regulatory requirements required for approval of any drug or drug-device combination products that Discovery Labs may develop, including that: (a) Discovery Labs and the U.S. Food and Drug Administration (FDA) or other regulatory authorities will not be able to agree on the matters raised during regulatory reviews, or Discovery Labs may be required to conduct significant additional activities to potentially gain approval of its product candidates, if ever, (b) the FDA or other regulatory authorities may not accept or may withhold or delay consideration of any of Discovery Labs' applications, or may not approve or may limit approval of Discovery Labs' products to particular indications or impose unanticipated label limitations, and (c) changes in the national or international political and regulatory environment may make it more difficult to gain FDA or other regulatory approval; risks relating to Discovery Labs' research and development activities, including (i) time-consuming and expensive pre-clinical studies, clinical trials and other efforts, which may be subject to potentially significant delays or regulatory holds, or fail, and (ii) the need for sophisticated and extensive analytical methodologies, including an acceptable biological activity test, if required, as well as other quality control release and stability tests to satisfy the requirements of the regulatory authorities; risks relating to Discovery Labs' ability to develop and manufacture drug products and capillary aerosolization systems for clinical studies, and, if approved, for commercialization of drug and combination drug-device products, including risks of technology transfers to contract manufacturers and problems or delays encountered by Discovery Labs, its contract manufacturers or suppliers in manufacturing drug products, drug substances and capillary aerosolization systems on a timely basis or in an amount sufficient to support Discovery Labs' development efforts and, if approved, commercialization; the risk that Discovery Labs may be unable to identify potential strategic partners or collaborators to develop and commercialize its products, if approved, in a timely manner, if at all; the risk that Discovery Labs will not be able in a changing financial market to raise additional capital or enter into strategic alliances or collaboration agreements, or that the ongoing credit crisis will adversely affect the ability of Discovery Labs to fund its activities, or that additional financings could result in substantial equity dilution; the risk that Discovery Labs will not be able to access credit from its committed equity financing facilities (CEFFs), or that the minimum share price at which Discovery Labs may access the CEFFs from time to time will prevent Discovery Labs from accessing the full dollar amount potentially available under the CEFFs; the risk that Discovery Labs or its strategic partners or collaborators will not be able to retain, or attract, qualified personnel; the risk that Discovery Labs will be unable to regain compliance with The Nasdaq Capital Market listing requirements prior to the expiration of the additional grace period currently in effect, which could cause the price of Discovery Labs' common stock to decline; the risk that recurring losses, negative cash flows and the inability to raise additional capital could threaten Discovery Labs' ability to continue as a going concern; the risks that Discovery Labs may be unable to maintain and protect the patents and licenses related to its products, or other companies may develop competing therapies and/or technologies, or health care reform may adversely affect Discovery Labs; risks of legal proceedings, including securities actions and product liability claims; risks relating to health care reform; and other risks and uncertainties described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.
CONTACT: Discovery Laboratories, Inc.
John G. Cooper, EVP and Chief Financial Officer
215-488-9300
Keryx Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colorectal Cancer
Date : 06/08/2010 @ 9:00AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=43138869&symbol=KERX
Data Reported at 46th Annual ASCO Meeting Confirms a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm
PR Newswire
NEW YORK, June 8
NEW YORK, June 8 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today reported final results on the clinical activity of KRX-0401 (perifosine), the Company's oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, in combination with capecitabine (Xeloda®) as a treatment for advanced, metastatic colorectal cancer. Abstract #3531, entitled, "Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colorectal cancer (mCRC)," is being presented today in a poster discussion held during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
STUDY DESIGN:
In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, heavily pre-treated patients with second- or third-line metastatic colorectal cancer were randomized to receive capecitabine (a chemotherapy used in advanced metastatic colorectal cancer which is marketed by Roche as Xeloda®) at 825 mg/m2 BID (total daily dose of 1650 mg/m2) on days 1 – 14 every 21 days plus either perifosine or placebo at 50 mg daily. The study enrolled a total of 38 patients, 34 of which were third-line or greater. Median age of patients was 65 (32-83); 61% of the patients were male. Of the 38 patients enrolled, 35 patients were evaluable for response (20 patients on the perifosine + capecitabine arm and 15 patients on the placebo + capecitabine arm). Three patients on the placebo + capecitabine arm were not evaluable for response (2 patients were inevaluable due to toxicity (days 14, 46) and 1 was inevaluable due to a new malignancy on day 6). All patients in the perifosine + capecitabine arm were evaluable for response.The patients in the study were heavily pre-treated, with the arms well-balanced in terms of prior treatment regimens. The prior treatment regimens for all 38 patients are shown in the table below. Notably, all of the patients (with the exception of one CAP arm patient) had been treated with FOLFIRI and/or FOLFOX, almost 80% treated with Avastin®, and half treated with an EGFR antibody:
Prior RX
P-CAP (n=20)
CAP (n=18)
All Patients (n=38)
FOLFIRI
18 (90%)
16 (89%)
34 (89%)
FOLFOX
15 (75%)
13 (72%)
28 (74%)
FOLFIRI & FOLFOX
13 (65%)
12 (67%)
25 (66%)
Avastin®
15 (75%)
15 (83%)
30 (79%)
EGFR Antibody (1)
9 (45%)
10 (56%)
19 (50%)
5-FU Refractory Status
14 (70%)
13 (72%)
27 (71%)
Third Line or >
18 (90%)
16 (89%)
34 (89%)
(1) Prior treatment with Erbitux® and/or Vectibix®
The primary endpoint of this study was to measure Time to Progression (TTP). Overall Response Rate (ORR), defined as Complete Response (CR) + Partial Response (PR) by RECIST, and Overall Survival (OS) were measured as secondary endpoints.
STUDY RESULTS:
The P-CAP arm demonstrated a statistically significant advantage for TTP and OS, as well as for the percentage of patients achieving Stable Disease (SD) or better lasting 12 or more weeks, as compared to the CAP arm. The P-CAP arm demonstrated a greater than 60% improvement in OS, a more than doubling of median TTP, and almost a doubling of the percentage of patients achieving SD or better. In addition, the ORR was 20% (including one CR, and durable responses) in the P-CAP arm versus 7% in the CAP arm.
The final efficacy results are as follows:
ALL EVALUABLE PATIENTS (n=35):
Group
n
CR
n
(%)
PR
n (%)
Duration of
Response
> SD
(min 12 wks)
n (%)
p=0.036
PD< 12 wks
n (%)
Median TTP
Wks
p=0.0012
Median OS*
Months
p=0.0161
P-CAP
20
1 (5%)
3 (15%)
CR: 36 m
11 (55%)
5 (25%)
28
[95% CI (12-48)]
17.7
[95% CI (8.5-24.6)]
PR: 21, 19, 11 m
CAP
15
0
1 (7%)
PR: 7 m
5 (33%)
9 (60%)
11
[95% CI (9-15.9)]
10.9
[95% CI (5-16.9)]
*Survival is calculated from date of randomization until the date of death from any cause, whether or not additional therapies were received after removal from treatment.
Of notable interest were the patients who were previously refractory to a 5-FU based regimen. The P-CAP arm again demonstrated a statistically significant increase in both TTP and OS compared to the CAP arm. The final data is illustrated below:
5-FU REFRACTORY PATIENTS (n=25):
Group
n (%)
PR
n (%)
Duration
of
Response
> SD (min 12 wks)
n (%)
p=0.066
PD 10% incidence for the P-CAP arm versus CAP arm as follows: hand-foot syndrome (30% vs. 0%), anemia (15% vs. 0%), fatigue (0% vs. 11%) and abdominal pain (5% vs. 11%). Of note, incidence of Grade 1 and 2 hand-foot syndrome was similar in both the P-CAP and CAP arms (25% vs. 22%, respectively). Hand-foot syndrome is a reported adverse event with capecitabine monotherapy. Patients who remained on treatment longer in the Phase 2 study had a greater chance to develop hand-foot syndrome as illustrated by a median time to onset of Grade 3 and 4 hand-foot syndrome in the P-CAP arm of 19 weeks.
Based on the Phase 2 data, a Phase 3 randomized double-blind trial comparing perifosine + capecitabine vs. placebo + capecitabine in patients with advanced refractory colorectal cancer (X-PECT trial), under Special Protocol Assessment (SPA) from the FDA, is open and enrolling patients at multiple centers throughout the US.
Commenting on the data, Dr. Johanna Bendell, Director of GI Oncology Research at Sarah Cannon Research Institute in Nashville, TN, stated, "As the final randomized Phase 2 data confirmed the promising activity of perifosine plus capecitabine compared to placebo plus capecitabine, I believe the ongoing X-PECT trial will soon provide us an answer as to the role of perifosine in the treatment of patients with refractory colorectal cancer." Dr. Bendell is the Principal Investigator for the Phase 3 X-PECT trial.
Dr. Cathy Eng, Associate Medical Director for Colorectal Cancer at MD Anderson Cancer Center in Houston, Texas, and co-investigator in the X-PECT trial stated, "The data from the randomized Phase 2 trial continues to demonstrate the promising activity of perifosine (an oral Akt pathway inhibitor) for response, PFS, and OS in the care of previously treated, advanced colorectal cancer. We look forward to collaborating in the X-PECT trial."
Ron Bentsur, Chief Executive Officer of Keryx, commented "We are pleased by the final data, showing the promising activity of the perifosine + capecitabine combination in this very advanced colorectal cancer patient population. We believe that our Phase 3 study, in agreement with the FDA under SPA, has been designed to confirm the activity observed in this randomized Phase 2 trial."
A copy of the poster is available via request to Keryx.
Perifosine is also currently in a Phase 3 trial, under Special Protocol Assessment (SPA), for the treatment of relapsed/refractory multiple myeloma.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.
About Colorectal Cancer
According to the American Cancer Society, colorectal cancer is the third most common form of cancer diagnosed in the United States. It is estimated that over 146,000 people were diagnosed with some form of colorectal cancer with over 49,000 patients dying from colorectal cancer in 2009. Surgery is often the main treatment for early stage colorectal cancer. When colorectal cancer metastasizes (spreads to other parts of the body such as the liver) chemotherapy is commonly used. Treatment of patients with recurrent or advanced colorectal cancer depends on the location of the disease. Chemotherapy regimens (i.e. FOLFOX or FOLFIRI either with or without bevacizumab) have been shown to increase survival rates with some stages of colorectal cancer. Currently, there are seven approved drugs for patients with metastatic colorectal cancer: 5-fluorouracil (5-FU), capecitabine (Xeloda®), irinotecan (Camptosar®), oxaliplatin (Eloxatin®), bevacizumab (Avastin®), cetuximab (Erbitux®) , and panitumumab (Vectibix®). Depending on the stage of the cancer, two or more of these types of treatment may be combined at the same time or used after one another. For example, FOLFOX combines 5-FU, leucovorin and oxaliplatin and FOLFIRI combines 5-FU, leucovorin and irinotecan. Avastin®, a VEGF monoclonal antibody inhibitor, is commonly administered together with FOLFIRI and FOLFOX. Typically, patients who fail FOLFIRI and/or FOLFOX (+ Avastin) and who are considered EGFR-positive (non-mutated, wild-type KRAS status), receive the EGFR monoclonal antibody inhibitors Erbitux® or Vectibix®. However, patients who continue to progress beyond these treatments have a poor prognosis.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Lauren Fischer
Director, Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5962
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors,
Date : 06/07/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=43119132
Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma
Perifosine demonstrated to be safe and tolerable, with early signs of clinical benefit in advanced refractory pediatric neuroblastoma patients
PR Newswire
NEW YORK, June 7
NEW YORK, June 7 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL. Perifosine is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. This study, conducted by the Memorial Sloan-Kettering Cancer Center pediatric group, marks the first time that perifosine has been administered in a pediatric patient setting.
Study Design: This Phase I Study of Perifosine for Recurrent Pediatric Solid Tumors is a single center, open-label, dose-escalating study to assess safety, tolerability, pharmacokinetics (PK), and to identify any dose limiting toxicity (DLT) of single agent perifosine in pediatric patients with any solid tumor that has failed standard therapy. Eleven patients (4 males, 7 females), at a median age of 13 years (5-18) were treated in this study to date. The following tumor types were treated thus far: high-grade glioma (5), medulloblastoma (2), neuroblastoma (3), and ependymoma (1). Most patients were heavily pretreated, with a median of three prior lines of therapy. Cohorts of three patients were treated at three dose levels: 25mg/m2/day, 50mg/m2/day and 75mg/m2/day using 50mg tablets of perifosine after a loading dose on day 1, and taking into account the drug's long half-life (>100hrs). No DLTs were observed at any of the three dose levels; dose level 4 is currently open for accrual. PK data thus far suggests similar drug absorption by pediatric patients relative to adult patients treated with single agent perifosine.
Of particular interest are the early signs of clinical activity observed in two of the three patients with Stage 4 refractory neuroblastoma. Both patients were refractory to prior treatments upon entering the study and achieved stable disease for 48 weeks and 55+ weeks (ongoing). The investigators concluded that perifosine is well-tolerated in children with recurrent solid tumors and that these early signals of activity warrant further investigation in patients with advanced neuroblastoma and select brain tumors. Recently, NCI investigators published in vitro and in vivo data demonstrating that perifosine targets the activation of Akt in neuroblastoma cells and xenografts, significantly inhibits tumor growth in vivo and improves the survival of mice bearing neuroblastoma tumors.
Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We are pleased at the safety and tolerability of single agent perifosine in pediatric patients and encouraged by the early signals of clinical benefit in neuroblastoma, as noted by the investigators. We are grateful to the researchers and we look forward to exploring perifosine's potential in future pediatric settings, including neuroblastoma."
Perifosine is currently in Phase 3 clinical development for refractory advanced colorectal cancer and multiple myeloma, both of these Phase 3 programs being conducted under Special Protocol Assessment (SPA) agreements with the FDA with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.
A copy of the related abstract, #9540, entitled "Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors," lead author Oren J. Becher, M.D., can be accessed through the ASCO website, www.asco.org. A copy of the poster may be obtained by contacting the Company.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the ASCO website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
Keryx Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colorectal Cancer
Date : 06/08/2010 @ 9:00AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=43138869&symbol=KERX
Data Reported at 46th Annual ASCO Meeting Confirms a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm
PR Newswire
NEW YORK, June 8
NEW YORK, June 8 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today reported final results on the clinical activity of KRX-0401 (perifosine), the Company's oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, in combination with capecitabine (Xeloda®) as a treatment for advanced, metastatic colorectal cancer. Abstract #3531, entitled, "Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colorectal cancer (mCRC)," is being presented today in a poster discussion held during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
STUDY DESIGN:
In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, heavily pre-treated patients with second- or third-line metastatic colorectal cancer were randomized to receive capecitabine (a chemotherapy used in advanced metastatic colorectal cancer which is marketed by Roche as Xeloda®) at 825 mg/m2 BID (total daily dose of 1650 mg/m2) on days 1 – 14 every 21 days plus either perifosine or placebo at 50 mg daily. The study enrolled a total of 38 patients, 34 of which were third-line or greater. Median age of patients was 65 (32-83); 61% of the patients were male. Of the 38 patients enrolled, 35 patients were evaluable for response (20 patients on the perifosine + capecitabine arm and 15 patients on the placebo + capecitabine arm). Three patients on the placebo + capecitabine arm were not evaluable for response (2 patients were inevaluable due to toxicity (days 14, 46) and 1 was inevaluable due to a new malignancy on day 6). All patients in the perifosine + capecitabine arm were evaluable for response.The patients in the study were heavily pre-treated, with the arms well-balanced in terms of prior treatment regimens. The prior treatment regimens for all 38 patients are shown in the table below. Notably, all of the patients (with the exception of one CAP arm patient) had been treated with FOLFIRI and/or FOLFOX, almost 80% treated with Avastin®, and half treated with an EGFR antibody:
Prior RX
P-CAP (n=20)
CAP (n=18)
All Patients (n=38)
FOLFIRI
18 (90%)
16 (89%)
34 (89%)
FOLFOX
15 (75%)
13 (72%)
28 (74%)
FOLFIRI & FOLFOX
13 (65%)
12 (67%)
25 (66%)
Avastin®
15 (75%)
15 (83%)
30 (79%)
EGFR Antibody (1)
9 (45%)
10 (56%)
19 (50%)
5-FU Refractory Status
14 (70%)
13 (72%)
27 (71%)
Third Line or >
18 (90%)
16 (89%)
34 (89%)
(1) Prior treatment with Erbitux® and/or Vectibix®
The primary endpoint of this study was to measure Time to Progression (TTP). Overall Response Rate (ORR), defined as Complete Response (CR) + Partial Response (PR) by RECIST, and Overall Survival (OS) were measured as secondary endpoints.
STUDY RESULTS:
The P-CAP arm demonstrated a statistically significant advantage for TTP and OS, as well as for the percentage of patients achieving Stable Disease (SD) or better lasting 12 or more weeks, as compared to the CAP arm. The P-CAP arm demonstrated a greater than 60% improvement in OS, a more than doubling of median TTP, and almost a doubling of the percentage of patients achieving SD or better. In addition, the ORR was 20% (including one CR, and durable responses) in the P-CAP arm versus 7% in the CAP arm.
The final efficacy results are as follows:
ALL EVALUABLE PATIENTS (n=35):
Group
n
CR
n
(%)
PR
n (%)
Duration of
Response
> SD
(min 12 wks)
n (%)
p=0.036
PD< 12 wks
n (%)
Median TTP
Wks
p=0.0012
Median OS*
Months
p=0.0161
P-CAP
20
1 (5%)
3 (15%)
CR: 36 m
11 (55%)
5 (25%)
28
[95% CI (12-48)]
17.7
[95% CI (8.5-24.6)]
PR: 21, 19, 11 m
CAP
15
0
1 (7%)
PR: 7 m
5 (33%)
9 (60%)
11
[95% CI (9-15.9)]
10.9
[95% CI (5-16.9)]
*Survival is calculated from date of randomization until the date of death from any cause, whether or not additional therapies were received after removal from treatment.
Of notable interest were the patients who were previously refractory to a 5-FU based regimen. The P-CAP arm again demonstrated a statistically significant increase in both TTP and OS compared to the CAP arm. The final data is illustrated below:
5-FU REFRACTORY PATIENTS (n=25):
Group
n (%)
PR
n (%)
Duration
of
Response
> SD (min 12 wks)
n (%)
p=0.066
PD 10% incidence for the P-CAP arm versus CAP arm as follows: hand-foot syndrome (30% vs. 0%), anemia (15% vs. 0%), fatigue (0% vs. 11%) and abdominal pain (5% vs. 11%). Of note, incidence of Grade 1 and 2 hand-foot syndrome was similar in both the P-CAP and CAP arms (25% vs. 22%, respectively). Hand-foot syndrome is a reported adverse event with capecitabine monotherapy. Patients who remained on treatment longer in the Phase 2 study had a greater chance to develop hand-foot syndrome as illustrated by a median time to onset of Grade 3 and 4 hand-foot syndrome in the P-CAP arm of 19 weeks.
Based on the Phase 2 data, a Phase 3 randomized double-blind trial comparing perifosine + capecitabine vs. placebo + capecitabine in patients with advanced refractory colorectal cancer (X-PECT trial), under Special Protocol Assessment (SPA) from the FDA, is open and enrolling patients at multiple centers throughout the US.
Commenting on the data, Dr. Johanna Bendell, Director of GI Oncology Research at Sarah Cannon Research Institute in Nashville, TN, stated, "As the final randomized Phase 2 data confirmed the promising activity of perifosine plus capecitabine compared to placebo plus capecitabine, I believe the ongoing X-PECT trial will soon provide us an answer as to the role of perifosine in the treatment of patients with refractory colorectal cancer." Dr. Bendell is the Principal Investigator for the Phase 3 X-PECT trial.
Dr. Cathy Eng, Associate Medical Director for Colorectal Cancer at MD Anderson Cancer Center in Houston, Texas, and co-investigator in the X-PECT trial stated, "The data from the randomized Phase 2 trial continues to demonstrate the promising activity of perifosine (an oral Akt pathway inhibitor) for response, PFS, and OS in the care of previously treated, advanced colorectal cancer. We look forward to collaborating in the X-PECT trial."
Ron Bentsur, Chief Executive Officer of Keryx, commented "We are pleased by the final data, showing the promising activity of the perifosine + capecitabine combination in this very advanced colorectal cancer patient population. We believe that our Phase 3 study, in agreement with the FDA under SPA, has been designed to confirm the activity observed in this randomized Phase 2 trial."
A copy of the poster is available via request to Keryx.
Perifosine is also currently in a Phase 3 trial, under Special Protocol Assessment (SPA), for the treatment of relapsed/refractory multiple myeloma.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.
About Colorectal Cancer
According to the American Cancer Society, colorectal cancer is the third most common form of cancer diagnosed in the United States. It is estimated that over 146,000 people were diagnosed with some form of colorectal cancer with over 49,000 patients dying from colorectal cancer in 2009. Surgery is often the main treatment for early stage colorectal cancer. When colorectal cancer metastasizes (spreads to other parts of the body such as the liver) chemotherapy is commonly used. Treatment of patients with recurrent or advanced colorectal cancer depends on the location of the disease. Chemotherapy regimens (i.e. FOLFOX or FOLFIRI either with or without bevacizumab) have been shown to increase survival rates with some stages of colorectal cancer. Currently, there are seven approved drugs for patients with metastatic colorectal cancer: 5-fluorouracil (5-FU), capecitabine (Xeloda®), irinotecan (Camptosar®), oxaliplatin (Eloxatin®), bevacizumab (Avastin®), cetuximab (Erbitux®) , and panitumumab (Vectibix®). Depending on the stage of the cancer, two or more of these types of treatment may be combined at the same time or used after one another. For example, FOLFOX combines 5-FU, leucovorin and oxaliplatin and FOLFIRI combines 5-FU, leucovorin and irinotecan. Avastin®, a VEGF monoclonal antibody inhibitor, is commonly administered together with FOLFIRI and FOLFOX. Typically, patients who fail FOLFIRI and/or FOLFOX (+ Avastin) and who are considered EGFR-positive (non-mutated, wild-type KRAS status), receive the EGFR monoclonal antibody inhibitors Erbitux® or Vectibix®. However, patients who continue to progress beyond these treatments have a poor prognosis.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Lauren Fischer
Director, Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5962
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
Cardium Announces Collagen Supply Agreement with Devro Medical for Planned Market Launch of Excellagen Product Candidate and Reports on Further Positive Healing Effects
Date : 06/08/2010 @ 9:00AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&article=43138780&symbol=CXM
Final Data Analysis of Phase 2b Matrix Clinical Study Shows Statistically Significant Acceleration of Wound Healing Following One-Time Treatment
PR Newswire
SAN DIEGO, June 8
SAN DIEGO, June 8 /PRNewswire-FirstCall/ --
Cardium Therapeutics (NYSE Amex: CXM) today announced that its wholly-owned subsidiary, Tissue Repair Company, has entered into a multi-year supply agreement with Devro Medical Limited, part of Devro plc, a public limited company registered in Scotland, for the supply of highly-refined fibrillar bovine Type I collagen, an important component of Cardium's new Excellagen formulated collagen product candidate, which is pending FDA 510(k) clearance. A detailed slide presentation on the final data analysis of the Matrix Phase 2b clinical study, demonstrating a statistically significant acceleration of wound healing following a one-time application of the Excellagen product candidate, is now available at the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
(Photo: http://photos.prnewswire.com/prnh/20100608/LA17012)
(Photo: http://www.newscom.com/cgi-bin/prnh/20100608/LA17012)
(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)
Under this supply agreement, the collagen component of Excellagen will be manufactured at Devro's new cGMP manufacturing facility which is currently undergoing final process validation activities and awaiting a formal accreditation audit for ISO certifications. Devro also plans to establish a Device Master File with the FDA following completion of ISO certifications of other component manufacturing processes. In addition, Cardium has also entered into a clinical manufacturing and supply agreement with its U.S.-based fill and finish contract manufacturer to provide final processing and assembly of the market ready Excellagen product.
"After a detailed review of potential commercial suppliers of medical-grade collagen fiber formulations for our Excellagen product candidate, we believe that Devro Medical is uniquely qualified to ensure a timely supply of highly-refined material of a quality and consistency designed for use in treating diabetic wounds and other important medical applications. Rigorous specifications have been engineered into our formulated collagen by our researchers, which we believe contribute to the significant healing response that has been observed and now reported in our recently completed Matrix Phase 2b clinical study," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium.
Mr. Reinhard added that "the final steps for regulatory clearance of Excellagen involve providing confirmatory product and process testing information obtained with the final market-ready product. With our commercial supplier now in place, we expect to have market-ready material finalized and tested within the next quarter so that we can be in position for final FDA clearance and commercial launch. In parallel, we are now initiating activities associated with launch, including packaging and other final product requirements, and are in discussions with potential commercialization partners for the marketing and sale of Excellagen in the U.S. and internationally."
Reporting on the final data analysis of the Excellagen cohorts from the Matrix Phase 2b clinical study, Mr. Reinhard stated that, "Excellagen appeared to be both safe and well tolerated and showed a statistically significant 173% relative improvement in the acceleration of wound healing (reduction in wound size) during the first week following a one-time application (generally applied following surgical debridement) compared to patients receiving standard of care therapy." He also noted that, "Researchers believe that more frequent treatments of Excellagen in response to observed wound healing rate slowdowns and plateaus and in association with all surgical debridement procedures during a 12-week treatment regimen may potentially offer the opportunity to substantially increase the already robust healing effect that was reported in the Matrix study (which specified only one or two administrations during the 12-week study period). Given this important new supplemental data, we plan to continue building on our unique initial wound management product candidate with the potential development of new product opportunities by incorporating other agents into the Excellagen formulation, including antimicrobials, DNA and/or other biologics, which would be designed to address particular aspects of the wound care market."
About Excellagen and Final Data Analysis From the Matrix Phase 2b Clinical Study
Excellagen is a highly-refined fibrillar bovine Type I collagen-based topical gel (2.6% collagen concentration) that is formulated to include structural stabilizers, hydrolytic enzyme inhibitors, and bacteriostatic agents. Excellagen was initially developed as a flowable matrix to support, preserve and nurture complex advanced DNA-based regenerative medicine biologics. Excellagen has been evaluated in a controlled, double-blind randomized, multi-center Phase 2b clinical study at 23 U.S.-based medical centers for the treatment of chronic non-healing diabetic foot ulcers (the Matrix Study).
Based on the 510(k) FDA submission, Excellagen will be indicated for the management of wounds, including partial and full thickness wounds, pressure ulcers, diabetic ulcers, chronic vascular ulcers and certain other wounds, such as surgical and trauma wounds. Excellagen's initial marketing focus will be directed to the care of diabetic ulcers based on experience and clinical findings from the Matrix Study. Excellagen's product configuration is an easy-to-use, pre-filled sterile, single use syringe providing for easy topical application which requires refrigeration. ExcellagenXL kits will contain four single-use syringes, each containing 0.5cc of collagen gel, and four sterile applicator tips. ExcellagenFX kits (intended for treatment of larger and tunneling wounds) will contain one single-use syringe containing 4cc of collagen gel and one sterile applicator tip.
A final analysis of data from the Matrix Study indicates that the Excellagen product candidate appeared to be both safe and well tolerated, and showed a statistically significant acceleration of wound healing (as measured by a reduction in wound radius) during the first week following a one-time application (generally applied following surgical debridement) compared to patients receiving standard of care therapy. The clinical study protocol randomized Excellagen patients into two subgroups. The first group received only one Excellagen treatment over the 12-week study period, and the other subgroup received a second Excellagen dose four weeks after the initial treatment in patients not achieving complete wound closure during the four weeks following the initial treatment. Photographs of each wound (taken using standardized equipment and a ruler for calibration) were evaluated by blinded evaluators using computer-assisted planimetry at one and two weeks following Excellagen administration to identify biological activity based on healing effects and intended to provide guidance for the use of Excellagen in clinical practice.
Based on this analysis (n=47), in the first week following treatment, the radius of Excellagen-treated wounds decreased on average by 0.213 cm compared to 0.078 cm for standard of care-treated wounds (p = 0.018). The average ulcer size at screening in both groups was ~3 cm(2). Excellagen also demonstrated numerically improved percent wound area reductions and wound closure rates at 12 weeks following one or two treatments compared to standard of care. The treatment effect was particularly evident in patients with larger-sized wounds (>3.0 cm(2)).
As previously reported, at 12-weeks 45% of all Excellagen-treated wounds achieved complete closure, compared to 31% in the standard of care group, representing a 45% overall improvement (based on one or two treatments per the study's formal protocol). For wounds >3 cm(2) in area at screening, 33% of Excellagen-treated wounds achieved closure by 12 weeks compared to 0% for standard of care. In addition, 74% of all Excellagen-treated wounds (that received one or two doses) achieved >/=90% wound area reduction at 12 weeks compared to 44% in the standard of care group, representing a 68% improvement.
Cardium believes that Excellagen represents a new class of collagen-based products optimized for ease of application, complete wound coverage without dripping and stimulation of the natural wound healing process through the promotion of cell migration and capillary in-growth to support tissue regeneration. The manufacturing process generates triple helical fibrillar collagen designed to mimic the structure and function of natural collagen. Excellagen fibrillar collagen gel is a specialized physiologic formulation that is believed to provide the following benefits for effective wound management: (1) provisional matrix for jump-starting the healing response; (2) effective substrate for repair cell adhesion, migration and proliferation; (3) conducive to granulation tissue formation and epithelialization; (4) localizes and stabilizes growth factors; and (5) promotes a balanced healing environment.
About Devro Medical
Devro Medical is part of the Devro group, the world's largest collagen processor. Devro has been supplying technically advanced collagen products for medical device production for more than 20 years. The company sources bovine collagen from Australia and processes it to exacting standards and customer specifications in clean room facilities in Scotland. Devro holds high level regulatory clearances and quality approvals to simplify its customer's product development and the sale of their collagen-based devices in all parts of the world. For more information about Devro, visit www.devromedical.com.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that Devro's new cGMP manufacturing facility or other manufacturing facilities involved with the production of the collagen component will receive formal accreditation for ISO certifications or will successfully establish a Device Master File with FDA following completion of ISO certifications; that Devro will be able to ensure an ample and timely supply of collagen; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the U.S. Food and Drug Administration will grant marketing clearance of the Excellagen product candidates or that we or a partner can successfully introduce these or additional products into advanced wound care markets; that Excellagen, Excellarate or our other candidates will prove to be sufficiently safe and effective, or that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the Excellagen or Excellarate product candidates offer the potential for simpler or more cost-effective treatment for physicians and patients than other FDA-approved products that currently are or will be on the market; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that discussions with potential strategic partners will be successful or that any partner will be able to efficiently and effectively commercialize Excellagen in U.S. or international markets; or that third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2010 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.
Cardium Therapeutics™ and Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.
Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™ and Osteorate™
are trademarks of Tissue Repair Company.
SOURCE Cardium Therapeutics
Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial
Date : 06/07/2010 @ 3:00PM
Source : MarketWire
Stock : Sunesis Pharmaceuticals, Inc. (SNSS)
http://ih.advfn.com/p.php?pid=nmona&article=43126377&symbol=N^SNSS
SOUTH SAN FRANCISCO, CA -- (Marketwire)
06/07/10
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced updated clinical data from Phase 2 clinical studies of the Company's lead drug candidate, voreloxin, in acute myeloid leukemia (AML) and platinum-resistant ovarian cancer. The results were presented today at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The presentations are available on the Sunesis website at www.sunesis.com.
Clinical data from the Sunesis' Phase 2 clinical trial of voreloxin in combination with cytarabine in first relapsed or primary refractory AML exhibit a meaningful improvement in overall survival relative to literature-based values reported for current treatment standards of care, including cytarabine-based regimens. These positive clinical findings, along with formal feedback from both U.S. and EU regulatory agencies, support Sunesis' plan to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year.
"Across both AML studies, either as a single agent in frontline elderly AML or in combination with cytarabine in relapsed/refractory AML, voreloxin has consistently achieved clinically meaningful remission rates balanced with impressively low all-cause early mortality," said Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina and a clinical study investigator for both Phase 2 AML clinical trials. "There remains a significant and enduring unmet need for new therapies among patients with this disease. These results merit investigation in a larger outcome study in AML and I look forward to actively participating in Sunesis' planned Phase 3 clinical trial in relapsed/refractory AML."
"Data from these Phase 2 trials underscore voreloxin's potential as a treatment for both hematologic cancers and solid tumors," said Steven Ketchum, Ph.D., Senior Vice President of Research and Development at Sunesis. "In particular, in our Phase 2 trial of relapsed/refractory AML, voreloxin in combination with cytarabine has demonstrated impressive survival outcomes, leading us to focus our initial development and registration efforts on this patient population. Based on our substantial Phase 2 dataset, combined with our careful review of literature and input from clinical advisors and regulatory agencies, we are confident that our planned Phase 3 trial is rigorously designed to detect a significant difference in overall survival."
With 450 evaluable patients, the Phase 3 clinical trial will have 90% power to detect a 40% difference in overall survival. In this trial, there will be a single prespecified interim analysis by an independent Data Safety Monitoring Board (DSMB) which will enable the DSMB to implement a one-time sample size adjustment of 225 additional evaluable patients to maintain adequate power across a broader range of potential survival outcomes. Sunesis' ongoing focus is directed toward the initiation of this multinational pivotal Phase 3 trial later this year.
Phase 2 Clinical Trial of Voreloxin in Combination with Cytarabine in Relapsed/Refractory AML - Abstract #6526
In a poster presentation and poster discussion session, investigators presented data from a Phase 2 clinical trial testing voreloxin in combination with cytarabine, a widely used chemotherapy, in patients with relapsed or refractory AML. In this trial, a total of 69 patients with first relapse or primary refractory AML have been treated at doses of 80 to 90 mg/m2 of voreloxin, in addition to either bolus or continuous infusion cytarabine.
Among evaluable first relapse (n=36) and primary refractory patients (n=33), median overall survival is 7.1 months. Of these patients, over 80% were either primary refractory or had an initial first remission (CR1) of less than 12 months. 20 patients are still in survival follow-up and are beyond the current median; 12 of these patients have survived out to one year or more as of the most recent evaluation.
Preliminary median leukemia-free survival (LFS) is 10.8 months.
The overall remission rate was 29% with the vast majority being complete remissions (17 of 20).
Infection-related toxicities were the most common Grade 3 or higher non-hematologic adverse events, all of which were expected. In addition, Grade 3 or higher oral mucositis was observed. The combination of voreloxin and cytarabine, regardless of cytarabine schedule, did not appear to exacerbate mucositis.
All-cause mortality among these patients was 3% at 30 days and 9% at 60 days.
The dose regimen to be used in the pivotal Phase 3 trial is 90 mg/m2 of voreloxin given as a 10 minute infusion on days one and four and 1 g/m2 of bolus cytarabine given as a two hour infusion on days one through five.
Phase 2 Clinical Trial of Single Agent Voreloxin in Newly Diagnosed Elderly AML (REVEAL-1 Trial) - Abstract #6525
In a poster presentation and poster discussion session, investigators presented data from the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose optimization trial of single agent voreloxin in previously untreated, elderly AML patients who are unlikely to benefit from standard induction chemotherapy. 113 AML patients have been treated in the trial, 82 percent of whom had two or more adverse risk factors, including age greater than 70 and intermediate or unfavorable cytogenetics. Median age for patients in the trial was 74 years. The REVEAL-1 trial includes three dosing schedules. As previously reported, Schedule C (72 mg/m2 of voreloxin on days one and four) is the recommended dose regimen for further study.
For Schedule C (72 mg/m2, n=30), median overall survival was 7.7 months and one year survival is approximately 38%, with 33% of patients remaining in follow-up. Response rate (CR and CRp) was 38%; 30- and 60-day all-cause mortality were 7% and 17%, respectively.
The most common grade 3 or higher non-hematologic adverse events included upper GI mucosal inflammation and infection.
"For elderly AML patients that present with additional risk factors, options are often limited due to the patients' intolerance to standard treatment," said Farhad Ravandi, M.D., Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, and an investigator in the Phase 2 clinical trial. "Voreloxin has demonstrated both strong anti-leukemic activity and adequate tolerability in this population, a balance which has yielded encouraging survival outcomes. I look forward to seeing voreloxin developed further in this and other AML settings."
Phase 2 Clinical Trial of Single Agent Voreloxin in Women with Platinum-Resistant Ovarian Cancer - Abstract #5002
Final clinical data from the Phase 2 trial of single agent voreloxin in women with platinum-resistant ovarian cancer were also presented during an oral presentation at the ASCO 2010 Annual Meeting. Platinum resistance is defined as progression within six months of completing platinum-based chemotherapy or progression while on platinum-based chemotherapy. Patients may have received up to three prior platinum regimens plus one additional non-platinum cytotoxic regimen. For approximately one third of the patients studied, prior treatment with Doxil® had failed. A total of 143 patients were enrolled in the trial, and enrollment was completed in December of 2008. Three dose cohorts of voreloxin were studied, and the 60 mg/m2 of voreloxin given every four weeks used in Cohort B is the recommended dose regimen for further study.
Data from this Phase 2 trial demonstrated encouraging, durable anti-tumor activity across all three dose cohorts, with the majority of patients achieving stable disease or an objective response.
For Cohort B (n=37), 54% of patients achieved disease control including 11% objective response rate (ORR, 2 CRs and 2 PRs), low incidence of grade 3 or higher febrile neutropenia (16%) and a long progression-free survival, with one patient remaining on study after 26 cycles of voreloxin. Median progression-free survival (PFS) was 85 days.
Four PRs were achieved in the 44 women who were Doxil® failures for an ORR of 9%. 66% of these patients achieved disease control, and median PFS in Doxil® failure patients was 91 days.
Overall, the adverse event profile was similar across cohorts and voreloxin was generally well-tolerated. Grade 3 or higher adverse events occurring in more than 10% of patients included neutropenia, febrile neutropenia, and anemia, all of which were expected and reversible with standard care.
"Responses to single agent voreloxin observed in women with ovarian cancer for whom multiple prior therapies have failed, including some for whom both platinum-based chemotherapy and Doxil® had failed, are promising," said Hal Hirte, M.D., Associate Professor, McMaster University, Department of Oncology and Chief of Oncology, Juravinski Cancer Centre at Hamilton Health Sciences and an investigator for the Phase 2 clinical trial. "These data warrant further investigation of voreloxin in this vastly underserved patient population, both in this later stage, salvage setting and in earlier lines of therapy."
Conference Call Information
Sunesis will host a conference call and webcast slide presentation Tuesday, June 8th at 9:00 a.m. Eastern time. Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, will join the Sunesis senior management team in a discussion of the new Phase 2 data presented at ASCO and review the plans for the upcoming randomized, pivotal Phase 3 clinical trial evaluating the effect on overall survival of voreloxin in combination with cytarabine for the treatment of first relapsed or refractory AML. The call can be accessed by dialing (877) 303-9029 (U.S. and Canada) or (914) 495-8584 (international). To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on Sunesis' website for two weeks.
About Voreloxin
Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a fully enrolled single agent Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a fully enrolled Phase 2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. A Phase 2 single agent clinical trial in platinum-resistant ovarian cancer has also completed enrollment. Sunesis anticipates initiating a Phase 3 trial of voreloxin in AML in the second half of 2010.
About Acute Myeloid Leukemia
AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The National Cancer Institute estimated that nearly 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. in 2009. Additionally, it is estimated that prevalence of AML is approximately 25,000 in the U.S. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.
About Ovarian Cancer
In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2009 there were an estimated 21,550 new cases and more than 14,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse, and overall long-term survival has not changed significantly over the past 40 years in women with recurrent disease, with less than 30 percent of patients surviving for more than five years.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
This press release contains forward-looking statements, including without limitation statements related to voreloxin's efficacy, safety profile and effects as a single agent and in combination with other AML treatments, the planned commencement and timing of a pivotal Phase 3 clinical trial of voreloxin, and voreloxin's mechanism of action and results that may warrant further clinical evaluation of voreloxin. Words such as "support," "plan," "merit," "demonstrated," "designed," "will," "look forward to," "warrant," "potential," "leading," "confident," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include without limitation, risks related to Sunesis' need for additional funding to finance the voreloxin pivotal trial and to continue as a going concern, the risk that Sunesis' drug development activities for voreloxin could be halted or significantly delayed for various reasons, the risk that Sunesis' clinical studies for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical studies may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical studies, risks related to the manufacturing of voreloxin, and the risk that Sunesis' proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
NewCardio Announces Acceptance of Five Peer-Reviewed Publications
Date : 06/07/2010 @ 10:30AM
Source : Business Wire
Stock : NewCardio, Inc. (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=43121643&symbol=NWCI
NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that five of its most recent medical and technical submissions have been accepted for publication in prominent peer-reviewed medical journals. These publications will present important clinical data supporting the accuracy and effectiveness of its CardioBip™ and Cardio3KG™ products.
* The peer-reviewed cardiology journal Heart Rhythm, published by the Heart Rhythm Society, has accepted a manuscript entitled “Vectorcardiographic diagnosis of new and old left bundle branch block,” by Alexei Shvilkin, M.D., Ph.D., Kalon Ho, M.D., Peter Zimetbaum, M.D., and Mark Josephson M.D. of Beth Israel Deaconess Medical Center and Harvard Medical School, and Bosko Bojovic, Ph.D., Branislav Vajdic, Ph.D. and Ihor Gussak, M.D., Ph.D., of NewCardio. This study presents data showing the ability of the Cardio3KG to improve diagnosis of acute myocardial infarction in a subgroup of patients with significant ECG abnormalities prior to the acute event. Publication and release of the manuscript is anticipated this year.
* Two full-length manuscripts incorporating data from clinical studies of CardioBip have been selected by peer-reviewers for publication this year in the IEEE Engineering in Medicine and Biology Journal. The clinical studies were conducted in two distinct groups of cardiac disease patients: those with established coronary artery disease who are at increased risk of myocardial infarction, i.e. a heart attack; and patients with recurrent atrial fibrillation, who are at increased risk of stroke. In both groups, the data show that CardioBip accurately detected and wirelessly transmitted important electrocardiographic changes indicating increased risk of adverse cardiac events in these patients.
* In addition, the Journal of Electrocardiology plans to publish two editorials coauthored by Dr. Ihor Gussak, M.D., PhD, NewCardio’s Chief Medical Officer, with Drs. P. Bjerregaard, H. Nallapaneni, and R. Shah, in the September 2010 issue of the Journal. The editorials cover important aspects relating to clinical and drug-development aspects of the Short QT Interval and its pro-arrhythmic potential. The editorials are relevant to the Company’s QTinno™ product, and accurate detection and quantification of drug-induced risk of cardiac arrhythmias.
Branislav Vajdic, Ph.D., NewCardio’s CEO, commented, “We are delighted that the peer-reviewers from these prestigious journals selected these important manuscripts for publication, and are especially grateful to our outstanding academic medical collaborators who designed and carried out this work. These publications will add to the strong clinical evidence for the use of CardioBip and Cardio3KG in diagnosing and monitoring patients with coronary disease and atrial fibrillation, two very common and serious cardiac diseases. Moreover, we believe this acceptance for publication is further evidence that our products and solutions are gaining increasing recognition by the scientific and medical communities. In particular we are pleased that CardioBip is being seen as a real solution in the growing telemedicine arena.”
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors,
Date : 06/07/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=43119132
Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma
Perifosine demonstrated to be safe and tolerable, with early signs of clinical benefit in advanced refractory pediatric neuroblastoma patients
PR Newswire
NEW YORK, June 7
NEW YORK, June 7 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL. Perifosine is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. This study, conducted by the Memorial Sloan-Kettering Cancer Center pediatric group, marks the first time that perifosine has been administered in a pediatric patient setting.
Study Design: This Phase I Study of Perifosine for Recurrent Pediatric Solid Tumors is a single center, open-label, dose-escalating study to assess safety, tolerability, pharmacokinetics (PK), and to identify any dose limiting toxicity (DLT) of single agent perifosine in pediatric patients with any solid tumor that has failed standard therapy. Eleven patients (4 males, 7 females), at a median age of 13 years (5-18) were treated in this study to date. The following tumor types were treated thus far: high-grade glioma (5), medulloblastoma (2), neuroblastoma (3), and ependymoma (1). Most patients were heavily pretreated, with a median of three prior lines of therapy. Cohorts of three patients were treated at three dose levels: 25mg/m2/day, 50mg/m2/day and 75mg/m2/day using 50mg tablets of perifosine after a loading dose on day 1, and taking into account the drug's long half-life (>100hrs). No DLTs were observed at any of the three dose levels; dose level 4 is currently open for accrual. PK data thus far suggests similar drug absorption by pediatric patients relative to adult patients treated with single agent perifosine.
Of particular interest are the early signs of clinical activity observed in two of the three patients with Stage 4 refractory neuroblastoma. Both patients were refractory to prior treatments upon entering the study and achieved stable disease for 48 weeks and 55+ weeks (ongoing). The investigators concluded that perifosine is well-tolerated in children with recurrent solid tumors and that these early signals of activity warrant further investigation in patients with advanced neuroblastoma and select brain tumors. Recently, NCI investigators published in vitro and in vivo data demonstrating that perifosine targets the activation of Akt in neuroblastoma cells and xenografts, significantly inhibits tumor growth in vivo and improves the survival of mice bearing neuroblastoma tumors.
Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We are pleased at the safety and tolerability of single agent perifosine in pediatric patients and encouraged by the early signals of clinical benefit in neuroblastoma, as noted by the investigators. We are grateful to the researchers and we look forward to exploring perifosine's potential in future pediatric settings, including neuroblastoma."
Perifosine is currently in Phase 3 clinical development for refractory advanced colorectal cancer and multiple myeloma, both of these Phase 3 programs being conducted under Special Protocol Assessment (SPA) agreements with the FDA with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.
A copy of the related abstract, #9540, entitled "Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors," lead author Oren J. Becher, M.D., can be accessed through the ASCO website, www.asco.org. A copy of the poster may be obtained by contacting the Company.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the ASCO website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
ASCO Live Blog: Monday
By Adam Feuerstein
http://www.thestreet.com/story/10773771/1/asco-live-blog-monday.html?kval=dontmiss
KERX @ ASCO (Tuesday, June 8, 2010)
http://ih.advfn.com/p.php?pid=nmona&article=42926420&symbol=N^KERX
Gastrointestinal (Colorectal) Cancer
Abstract Title: Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).
Presentation Date/Time: Tuesday, June 8, 2010; 8:00 AM - 12:00 Noon with poster discussion from 11:45 am – 12:00 Noon
Author: Donald A. Richards, MD, PhD, Texas Oncology
Discussion Presenter: Wells Messersmith, MD, University of Colorado
Permanent Abstract ID: 3531
Location: S403, Poster Board #22, with discussion in S406
###############################################################################################
Abstract:
Background:
Perifosine (P), a synthetic alkylphospholipid, inhibits or modifies signal transduction pathways including AKT, MAPK and JNK. We previously reported initial results of a phase II randomized study of P-CAP vs. CAP which demonstrated improved clinical activity of P-CAP over CAP in pts with mCRC. We now report the final safety, overall response rate (ORR), time to progression (TTP) and overall survival (OS) results.
Methods:
Pts with 2nd or 3rd line mCRC and no previous CAP in metastatic setting were randomized to P-CAP (P 50 mg PO QD + CAP 825 mg/m2 PO BID d1-14) or CAP (placebo + CAP 825 mg/m2 PO BID d 1-14). Cycles were 21 days.
Results:
38 pts were randomized (20 P-CAP/18 CAP). Median age 67 (32-83); 61% male. Median prior Rx = 2 (1-5). Prior Rx of P-CAP arm vs. CAP arm: FOLFIRI (90% vs. 87%); FOLFOX (75% vs. 73%); bevacizumab (75% vs. 80%); EGFR antibody (45% vs. 60%); progressed on prior 5-FU-based Rx (70% vs. 73%). All 38 pts were evaluable for toxicity. Most frequent AEs (P-CAP vs. CAP): G3 /4: hand/foot syndrome (HFS) (30% vs. 0%), anemia (15% vs. 0%), fatigue (0% vs. 11%), bowel obstruction (0% vs. 11%); G1/2: diarrhea (65% vs. 28%), nausea (45% vs. 28%), fatigue (50% vs. 33%), HFS (25% vs. 22%). 35/38 pts were evaluable for response (3 CAP pts off study for AE). Results for P-CAP vs. CAP: ORR: 20% vs. 7%; Median TTP: 28 vs. 11 wks (p=0.012); and OS: 18 vs. 11 mos (p=0.0136). Subset analysis in pts with 5-FU refractory disease is shown in the Table.
Conclusions:
P-CAP is a well-tolerated regimen that has promising activity over CAP as 2nd or 3rd line therapy for pts with metastatic colorectal cancer. This improvement is consistent for the subset of pts with 5-FU refractory disease. A randomized phase III trial of P-CAP vs. CAP is planned for refractory colorectal cancer pts.
http://abstract.asco.org/AbstView_74_48640.html